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A Introduction 
1 Role of the immune system in tumorigenesis 
Benign as well as malign tumors are characterized by a variety of uncontrolled features (1). The immune 
system plays an important role to prevent the tumorigenic process: By constantly screening the body cells 
and eliminating altered ones it is supposed to ensure tissue integrity which is compromised not only by 
infected but also by tumor cells. Immune responses of the adaptive immune system are mediated by B 
and T lymphocytes (2). B lymphocytes (B cells) are associated with humoral immunity: Pathogens are 
neutralized by molecules such as antibodies which are found in extracellular fluids. In contrast, T 
lymphocytes (T cells) are part of the cell-mediated immunity: T cells themselves are involved in 
recognizing tumor or infected cells. They are divided into helper T cells (CD4+ cells) and cytotoxic T cells 
(CTLs; CD8+ cells). CD4+ cells detect foreign antigens in the extracellular compartment and help mediating 
immune responses by activating the innate immune system, B cells as well as CTLs (3-5). Nevertheless, 
they are also crucial for 
immunosuppressive mechanisms (6). CD8+ 
cells can recognize altered body cells due 
to viral or bacterial infection or malignancy 
and can eliminate those cells directly. 
Either way, recognition arises by 
interaction between the T-cell receptor 
(TCR) on the T cells and the major 
histocompatibility complex (MHC) on the 
target cell (Fig. 1). MHC class I is found on 
all nucleated body cells and screened by 
CD8+ cells whereas MHC class II is located 
on antigen-presenting cells (APCs) and 
interacts with CD4+ cells (7, 8). Small 
peptides derived as particles of proteins 
either found extracellularly (MHC class II) 
or derived of proteins synthesized in the 
cytosol of body cells (MHC class I) are 
constantly presented on MHC molecules 
(9). MHC class I binds peptides of 8 – 10 
amino acids (10), MHC class II of 11 – 30 
amino acids (11). These MHC-peptide 
complexes can be recognized by TCRs in 
Fig. 1: Interaction between CD4+ helper T cells and APCs. 
Helper T cells require antigen presentation of professional APCs. 
Antigen is presented on the MHC class II and recognized by the TCR 
of CD4+ T cells. Presence of coinhibitory and costimulatory 
molecules on APCs and T cells influence the efficacy of T-cell 
response: CD80 and CD86 expression on APCs can have a 
costimulatory or coinhibitory effect, dependent on the receptor 
they bind to on the T cell—CD28 as stimulator and CTLA-4 as 
inhibitor. PD-L1 is an effective inhibitor when binding to PD-1 
receptor on T cells and is found to be overexpressed on many 
cancers. Figure shows simplified schematic illustration. CD = cluster 
of differentiation, TCR = T-cell receptor, CTLA-4 = cytotoxic T 
lymphocyte-associated antigen 4, PD-(L)1 = programmed death 
(ligand) 1, MHC = major histocompatibility complex, APC = antigen-
presenting cell, DC = dendritic cell 
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case an additional second signal (CD80/86-CD28) is available. In 1989, Lurquin et al. published that T cells 
are generally capable of identifying tumor antigens (12). They found that CTLs were able to recognize a 
mutated self-peptide of P815 mastocytoma cancer cells in a murine model. They identified that the 
peptides had mostly a length of 8 to 10 amino acids, representing the proteins built within the cells. In 
the meantime, specific subsets of tumor antigens were discovered which can be distinguished depending 
on their specificity for tumor tissue: 
1.1 Antigens with low tumor specificity 
Tumor-associated antigens (TAAs) are present on normal body tissue and cancer cells. They are either 
expressed to a higher amount on tumor cells such as human epidermal growth factor receptor 2 (HER2) 
in breast cancer (13) or vascular endothelial growth factor (VEGF) in renal cell carcinoma (14) or they are 
specific for the tissue from which the tumor originated (tissue differentiation antigens). A variety of 
targetable tissue differentiation antigens are known such as Tyrosinase (15), carcinoembryonic antigen 
(CEA) (16), Melan-A (MART-1) (17) or CD19. The latter is expressed on B cells and harnessed as target of 
CAR-modified T-cell therapy with high response rates (18, 19). 
TAAs are found in the majority of individuals, which renders them applicable in immunotherapy for a 
large patient collective. On the other hand, since they are found on normal tissue, central tolerance can 
lead to decreased TCR-mediated responses. In addition to that, by targeting healthy cells, 
immunotherapy involving TAAs can lead to on-target off-tumor side effects (20), specified in 2.2. 
1.2 Antigens with high tumor specificity 
Cancer-germline antigens (CGAs; also known as cancer-testis antigens) are expressed on germ cells and 
trophoblast tissue (21) but also on a variety of solid tumors including metastatic melanoma, lung and 
breast carcinoma (22). They contain the MAGE and BAGE family among others (23). Since they have not 
been presented in the thymus during central selection, no tolerance induction is expected. In addition, 
they are not expected in normal tissue and therefore allow strictly tumor-specific targeting (24). Using 
CGAs for TCR-mediated immunotherapy can nevertheless cause severe side effects in case cross-
reactivity occurs (see 2.2). 
Tumor-specific antigens (TSA) are exclusively expressed on tumor cells. When targeted, they are not 
expected to provoke autoimmunological effects nor does central tolerance play a role since they differ 
from antigens on healthy tissue (25). Some TSAs are shared among patients such as the BCR-ABL fusion 
protein in chronic myeloid leukemia or the mutated proto-oncogene product KRAS in several cancer 
entities (26). However, most of them are unique to each patient and need to be identified in 
individualized approaches, as was performed in the present study. A procedure referred to as “reverse 
immunology” is applied based upon the assumption that somatic mutations can predict those TSAs (27). 
Therefore, the genome of the tumor is sequenced and neoepitopes can be predicted in silico. 
Introduction 
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The amount of mutations in a tumor—potentially resulting in TSAs—is called mutational burden/load. It 
varies among tumor entities, essentially depending on the mutagens the tumors were exposed to. High 
mutation burdens can be found in melanoma, lung, stomach, colorectal, endometrial, and cervical 
cancers (28). Pediatric tumors such as medulloblastoma (MB) are known to have a very low mutational 
load and low immunogenicity (29). However, even tumors with low mutational loads can mount a 
relevant T-cell response: Tran et al. identified mutation-specific CD4+ cells in a patient with 
cholangiocarcinoma which contained only 26 mutations (30). In addition, Leisegang et al. showed that 
targeting only one mutation was sufficient for eradication of a solid tumor by T-cell therapy (27). 
1.3 The concept of immunoediting 
Although tumors can express (neo)antigens readily recognized by the immune system, they manage to 
evade the body’s immune attack efforts. In 2007, Swann et al. observed that tumors expressing tumor-
associated glycoprotein (Tag) are able to develop in immunocompetent mice despite Tag-specific 
immune responses (31). In another study, 9 out of 10 patients with metastatic gastrointestinal cancers 
generated T-cell responses against somatic mutations expressed by their tumors (32). Other studies 
proved the existence of mutation-reactive CD4+ cells in a patient with metastatic epithelial cancer 
originating from the bile ducts (30). 
This paradoxical phenomenon of apparently unhindered cancer growth in a functional immune system is 
known as cancer immunoediting which is differentiated into the three phases elimination, equilibrium 
and escape (33): 
1.3.1 Elimination 
In the early 20th century, Paul Ehrlich postulated that the immune system is able to recognize and 
eliminate cancer cells (34, 35). Years later, Burnet and Thomas called this observation “immune 
surveillance” and described it as the continuous active effort of lymphocytes to detect and suppress 
carcinogenesis (36). In the elimination phase, the innate and adaptive immune systems manage to inhibit 
malignant growth. Several pro-inflammatory cytokines such as IL-12 and IFN-γ play a critical role in this 
phase (33). Natural killer (NK) cells-mediated killing of tumor cells initiates adaptive immune responses: 
NK cells promote the maturation of DCs and their migration to lymph nodes, which then prime T cells. 
The naïve T cells develop into CD8+ effector T cells that can now specifically target and kill tumor cells. 
T cells are the strongest effectors of the immune system. Their enrichment in the tumor tissue—then 
referred to as tumor infiltrating lymphocytes (TILs)—is associated with a better prognosis of patients with 
melanoma (37) and other types of cancer, such as ovarian adenocarcinoma (38). In addition, the 
presence of NK cells in the tumor is correlated with a better patient survival for gastric carcinoma (39), 
squamous cell lung carcinoma (40) and colorectal cancer (41). Those cell entities induce cell apoptosis via 
the granule exocytosis pathway using perforin (pfp) or the Fas pathway (33). Mice lacking perforin were 
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more susceptible to lymphomas (42) as well as injected tumor cell lines (33). An important cytokine, 
regarding promotion of tumor cell recognition and elimination, is IFN-γ. It is released not only by NK cells 
but also by mature differentiated CD8+ T cells and some types of CD4+ T cells, together with TNF-α. By 
upregulating the expression of MHC class I and MHC class II molecules on tumor cells as well as tumor-
resident APCs, both Th1 cytokines are able to enhance the immune response (43). IFN-γ-insensitive mice 
show increased tumor growth and frequency (44), especially when combined with deficiency of the p53 
tumor-suppressor gene (45). In addition, mice deficient of both pfp and IFN-γ are significantly less 
capable of preventing metastasis as compared with mice either pfp-deficient or IFN-γ-deficient. The latter 
two are both comparable in terms of susceptibility to mice depleted of NK cells (46).  
1.3.2 Equilibrium and escape 
The equilibrium phase can last for years (47): Tumor cells become resistant to the immune attack, due to 
immune selection. In this process, growth of tumor variants which are more durable towards the immune 
system is encouraged and immunogenicity of the tumor is reduced. 
During escape phase, the tumor starts to grow uncontrollably, achieving immunological tolerance. This is 
due to several mechanisms, affecting both effector and tumor cells: 
On the effector side, TILs are known to be impaired: Due to loss of their signal transducer chain, which is 
part of the TCR-CD3 complex, T-cell activation upon antigen binding is compromised (48). Moreover, 
Strønen et al. tested the responsiveness of unaltered T cells from healthy donors towards melanoma-
associated antigens from three melanoma patients (49). The donor-derived T cells were able to induce T-
cell responses against 11 of 57 predicted HLA–A*02:01–binding epitopes as opposed to the autologous 
TILs which had mounted responses to only 2 of the 57 epitopes. This suggests that the neglect of tumor 
antigens by TILs can be bypassed by using an allogenic T-cell repertoire, as performed in this project. 
On the other hand, the immunosuppressive tumor microenvironment plays an important role. Radoja et 
al. showed that impaired T-cell efficiency on the tumor site does not necessarily imply generally 
diminished T-cell function in a murine model (50). There are several cytokines, ligands and cell types 
involved in decreasing antitumor immunity: Programmed cell death 1 ligand 1 (PD-L1) is found on many 
cancer cells and inhibits tumor-specific T-cell response by binding its receptor programmed cell death 
protein 1 (PD-1) (51). PD-1 and cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) are inhibitory 
immune checkpoints. They are physiologically located on T cells in order to prevent overactivation. In 
tumor escape, PD-1 is exploited by tumors to suppress T-cell response (52, 53). Tumors also intervene 
directly into apoptosis mechanisms: On the one hand, they evade elimination by overexpressing anti-
apoptotic molecules (54). On the other, they are capable of inducing apoptosis in T cells by releasing pro-
apoptotic vesicles (55). Finally, they secrete soluble factors such as VEGF, which impair the development 
of DCs, as well as anti-inflammatory mediators such as TGF-β and IL-10 in order to escape immune attack 
(56, 57). A further mechanism exerted by tumor tissue is down-regulation of MHC molecules to reduce 
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antigen-presentation (27, 58). An important role is also attributed to regulatory T cells (Tregs), usually 
responsible for suppression of immune responses to prevent autoimmunity. They have been shown to 
increase in number in the periphery during cancer progression, thus contributing to immune escape of 
the tumor (59). 
2 Immunotherapy as a fourth pillar of cancer treatment 
Cornerstones in cancer treatment have been surgery, chemotherapy and radiotherapy, often combined 
to improve clinical outcome. Recently, immunotherapy has gained in importance, enhancing the body’s 
capacity of targeting malignant cells. 
An early immunotherapeutic approach was performed by William B. Coley (60): In 1893, he observed 
cancer regression in a patient suffering from erysipelas. He assumed that this was due to bacteria and 
developed a mixture of killed bacteria, which was used to fight cancer for decades. However, today 
researchers attribute the tumor decrease to the intense immune response, triggered by the infection. In 
1900, Paul Ehrlich developed the idea of “magic bullets”, today known as antibodies, which could target 
receptors on cancer cells or pathogens specifically without harming healthy tissue (61). 
Immune checkpoint inhibitors block molecules such as CTLA-4 and PD-1 and thereby lead to enhanced T-
cell response due to decreased inhibition of T cells. They have been effective in several malignances such 
as melanoma, non-small cell lung cancer, renal cell carcinoma and Hodgkin lymphoma (62, 63). However, 
experience in pediatric malignancies is limited: There are ongoing studies regarding Hodgkin's disease and 
non-Hodgkin's lymphoma and an upcoming trial concerning relapsed/refractory acute myeloid leukemia 
(64). 
Another recent immunotherapeutic approach implies the engineering of bispecific antibodies that can 
link T cells and target cells by binding to both of them and thereby activating the T cell. Blinatumomab 
targets CD3 (T cells) and CD19 molecules (leukemic blasts) and is used successfully for treatment of 
chemotherapy-refractory ALL (65). 
2.1 Peptide vaccination 
Peptide vaccination is intended to induce immune response by administering tumor-specific peptides. 
Peptide vaccines generally have a favorable toxicity profile, they are effective and easy to synthesize (66). 
However, are prone to rapid degradation by peptidases (67) and they can lead to a functional deletion of 
tumor-specific CTLs and therefore immune tolerance (68), further discussed in D5. Slingluff et al. were 
able to induce helper T-cell responses in a high percentage of patients suffering from melanoma by 
injecting a vaccine composed of six melanoma-associated peptides (69). Schwartzentruber et al. 
compared treatment of advanced stage melanoma patients with IL-12 alone to treatment with IL-12 
combined with a gp100 peptide vaccine (70). Patients treated with the vaccine showed significant 
improvement in clinical response and had a significantly longer progression-free survival. Another study 
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detected increase in disease-free survival in breast cancer patients upon treatment with E75 vaccine, 
which is derived from the HER2 protein (71). In addition to melanoma and breast cancer, cancer vaccines 
for several cancer entities have been included into clinical trials such as for lung cancer (72), pancreatic 
cancer (73), esophageal cancer (74), gastric cancer (75) and head and neck cancers (76).  
2.2 Adoptive T-cell transfer  
Adoptive T-cell transfer (ATT) launched a new era of immunotherapy, engaging the tumor cells 
specifically and effectively. In autologous ATT, endogenous T cells of the patients are extracted, expanded 
in vitro and finally administered back into the patient. 
Starting in the late 1980ies, Rosenberg et al. extracted tumor tissue of melanoma patients, isolated the 
TILs, expanded them ex vivo and infused them back into the patients. The reimplanted TILs showed 
increased activity but were not very efficacious, as only in one of eleven patients a complete T-cell 
response could be observed (77). In 2002, their group successfully improved persistence of transferred T 
cells and therefore efficacy by lymphodepletion of the patients prior to T-cell transfer (78, 79). Multiple 
independent studies analyzing ATT in metastatic melanoma have reported 40 – 50 % objective responses 
and even 10 – 25 % complete remissions in treated patients (80). Moreover, Tran et al. showed that the 
patients with cholangiocarcinoma mentioned in 1.2 experienced objective regression of metastases and 
stabilization of disease after infusion of a highly enriched population of TILs, 25 % of which consisted of 
mutation-specific CD4+ T cells (30). 
While ATT of TILs was very effective treating melanoma, TILs with antitumor reactivity are not present in 
many types of cancer (81). Regarding TILs derived from pediatric solid tumors, an early study examined 
osteosarcomas, Wilms' tumors, soft-tissue sarcomas and neuroblastomas (82): They were not able to 
identify TILs in most of the tumors nor 
could the TILs be expanded ex vivo 
sufficient for ATT. In order to enhance 
ATT efficacy, new strategies use 
genetically modified T cells either by 
implementing a TCR (83) or chimeric 
antigen receptor (CAR)(84), both 
capable of specifically targeting tumor 
antigens (Fig. 2). While ATT using 
engineered TCRs allows a highly 
specific immune attack, it also requires 
the identification, isolation and 
sequencing of tumor-specific TCRs. 
Tumor-specific TCRs are cloned and 
Fig. 2: Concept of adoptive T-cell transfer. 
Patient’s T cells are extracted, optionally modified genetically in vitro, 
expanded in number and infused back into the patient where they can 
enhance the immune response. Source: LUNGevitiy Foundation (2016) 
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transduced into T cells via retro- or lentiviral vectors (85, 86). Moreover, those TCRs have to recognize 
not only the peptide but also the combination with the MHC to which it is bound. CARs on the other hand 
are fusion molecules consisting of an antibody’s variable region bound to costimulatory and T-cell 
receptor subunits (CD3zeta). The CD3zeta and costimulatory domains allow T-cell activation and 
expansion upon antigen binding. CARs recognize their antigen in an MHC-independent manner (87), but 
are restricted to surface antigens. CD19-directed CAR T-cell therapy has proven to be very effective in 
relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) (88, 
89). In general, ATT has mediated considerable cancer regression in melanoma, cervical cancer, 
lymphoma, leukemia, bile duct cancer and neuroblastoma (79). 
However, there have been drawbacks in adoptive T-cell therapy due to TCR-mediated side effects which 
are classified into on-target/off-tumor and off-target/off-tumor side effects (90) and are both able to 
cause healthy tissue damage. In 2009, 36 patients were treated with TCR-transduced T cells targeting 
melanoma differentiation antigens Melan-A (MART-1) or gp100. A third of the patients showed cancer 
regression but half of the patients developed not only vitiligo but sometimes also destruction of 
melanocytes in the eye and the inner ear (on-target/off-tumor) (91). In a trial realized in 2013, myeloma 
and melanoma patients were treated with T cells engineered to express a MAGE-specific TCR. Due to 
cross-recognition of a similar peptide derived from the muscle protein Titin, the treatment led to fatal 
toxicity against cardiac tissue (92, 93). In an additional trial using TCRs against MAGE-derived epitopes, 
severe damage to the brain tissue was observed, leading to coma and death in several patients. This 
occurred as the TCR recognized a different but related epitope expressed at very low levels in the brain 
(94). Both examples constitute off-target/off-tumor side effects. Targeting neoepitopes derived from 
TSAs, as performed in this study, can help reduce toxicity from such off-tumor effects. 
3 Medulloblastoma, the most common malignant brain tumor in childhood 
Tumors of the central nervous system (CNS) account for about a fifth of childhood tumors and constitute 
the leading cause of cancer-related death in children (Fig. 3) (95, 96). Among malignant tumors of the 
CNS, MB is the most frequent one, located in the cerebellum. It is an aggressive, fast-growing, highly 
malignant cancer, classified as WHO grade IV. It mainly affects children between five and nine years, but 
can also develop in infants as well as adults, although rarely after the fourth decade of life (97). 
Primary symptoms in patients with MB are due to increased intracranial pressure, resulting in head ache, 
impaired vision, morning vomiting and altered mental status (98). Local damage of cerebellar structures 
manifests with ataxia, dizziness and general impairment of motor function. Secondary affected brain 
structures as well as frequently occurring metastases can imply further neurological deficits. 
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3.1 Classification and pathogenesis  
Recently, MB has been classified into four subgroups 
based on histology and molecular features (99), with 
a focus on molecular pathways (100). The subgroups 
comprise the Wnt group, the sonic hedgehog (SHH) 
group, as well as Group 3 and Group 4. In the latter 
three, MB arises from cerebellar progenitor cells. 
Underlying mutations either enhance the SHH 
pathway (SHH group) or include amplification of MYC 
or MYCN genes among others (Group 3 and 4) (101). 
Wnt-associated MBs, however, imply the Wnt 
pathway and arise from the lower rhombic lip. They 
are attributed the best prognosis whereas group-3 
MB patients have the worst outcome (102). 
In terms of histology, several subtypes are 
distinguished: classic, large cell/anaplastic (LCA), 
nodular/desmoplastic and MB with extensive 
nodularity (103). Among these, LCAs have the worst 
prognosis while nodular/desmoplastic histology has 
rather favorable outcomes. 
Although some mechanisms leading to development 
of MB are known, it generally remains a cancer with a 
heterogeneous origin. Like other pediatric tumors, it 
has a low somatic mutation burden compared to 
other solid tumors (104). Next-generation whole genome and exome sequencing have recently increased 
knowledge about genetic underlying aberrations. In three independent studies from 2012, the average 
number of somatic, non-silent mutations—single nucleotide variants (SNVs) and indels—per MB genome 
ranged from only ten to twelve (104-106). There was a positive correlation between patient age and 
mutation rate, implying that adult MBs harbor considerably more mutations. Genetic heterogeneity 
underlying MB was underscored by the fact that among all 2,102 mutated genes identified in the three 
studies there were only 12 genes recurrently mutated (107).  
Another large study of the genomic landscape of MB was recently performed by Northcott et al. who 
included whole genome and exome data of almost 500 untreated MB patients, ranging from 1 month to 
50 years (108). They discovered a median of 698 mutations. Driver mutations in the coding regions were 
located in genes PTCH1, DDX3X, KMT2D and others which were assigned to patients belonging to Group 3 
and Group 4. In Wnt-driven and SHH-driven MB, driver mutations were found in the genes of respective 
Fig. 3: Distribution of childhood cancer diagnoses per 
year. 
Tumors of the CNS, including medulloblastoma, account 
for about a fifth of childhood malignancies. Chart 
comprises patients aged 0 – 19. Source: American 
Cancer Society, Cancer Facts and Figures (2014) 
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pathways. Another reported gene found mutated in MB is the well-known tumor suppressor gene TP53. 
In contrast to these mutations associated with a proven impact on tumorigenesis of MB, Northcott et al. 
reported a great number of low-frequency gene alterations which are not yet examined, but with possibly 
crucial roles. 
3.2 Therapy 
Treatment of MB has improved significantly and combines surgical resection, chemotherapy and 
irradiation (109). Approximately 80 – 85 % of average-risk patients and up to 70 % of high-risk patients 
can be cured of their disease, depending on subgroups (110). However, persistent adverse effects of 
these multi-approach treatment regimens include developmental, neurological, neuroendocrine and 
psychosocial deficits (111). Especially very young patients are susceptible to irradiation which makes it 
necessary to carefully evaluate the involved benefit and potential damage. Moreover, relapse of MB, 
which occurs in 20 – 30 % (112), remains a major problem: It has presented altered biology resulting in a 
more aggressive, uncontrollable growth (113). In a retrospective study including 55 MB patients, they 
reported a median survival after relapse of less than a year and a 3-year survival of 18 % (114). 
4 Objective: Inducing a de novo immune response against tumor-derived peptides 
The goal of this project was to determine whether tumor-specific neoepitopes derived from variants of 
two MB patients prove to be immunogenic. Reverse immunology approach was applied to find patient-
specific neoepitopes: Tumor-specific non-synonymous mutations were identified by whole exome 
sequencing and confirmed by deep sequencing. MHC binding affinity to patients’ HLA types was 
predicted in silico and binding peptides were synthesized for immunogenicity testing. Blood cells from 
healthy donors provided DCs for antigen presentation of peptides to donor-derived autologous T cells. In 
case that the peptide/HLA combination was recognized by the T cells, a de novo T-cell response was 
induced. Memory cells were developed ensuring a quick reinitiation of response upon further antigen 
exposure. Eventually, after seven restimulations with antigen presentation, the epitope was added again 
to reinduce the T-cell response which was then measured and quantified by IFN-γ and TNF-α release. 
In this “proof of principle” experiment we investigate T-cell responses against neoantigens which could 
then have several implications: First, we want to prove that medulloblastoma potentially harbors 
neoepitopes capable of inducing an immune response. We want to confirm that unaltered third-party 
T cells are capable of recognizing tumor epitopes neglected by the patient’s endogenous TILs. Second, 
further investigations can identify the TCRs involved in positive T-cell responses, determine their 
sequences and synthesize them. Approaches such as TCR-transduced ATT or peptide vaccination using a 
patient-adjusted peptide cocktail could allow a completely individualized treatment, especially for 
advanced tumor patients, and thus create new therapeutic possibilities. 
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B Materials and Methods 
1 Materials 
1.1 Equipment and software 
Autoclaves VX-150 and DX-65, Systec, Linden, Germany 
Cell counting auxiliaries Cell Counting Chamber Neubauer, Chamber Depth 0.1 mm, Paul  
Marienfeld, Lauda-Königshofen, Germany 
Centrifuges Multifuge X3R and Mini Centrifuge Fresco 17, Heraeus, Hanau,  
Germany 
 Centrifuge 5810 R, Eppendorf, Hamburg, Germany 
Cooling units FD 7202, Bosch, Munich, Germany 
Freezer (-20 °C) Premium No Frost, Liebherr, Biberach an der Riß,  
Germany 
 Freezer (-86 °C) HERAfreeze HFU T Serie, Heraeus, Hanau, Germany 
 Cryogenic Freezer MVE 600 Serie, Chart, Luxemburg 
Flow cytometer BD LSRFortessa Cell Analyzer, BD, Franklin Lakes, USA 
Freezing container Nalgene Mr. Frosty, Thermo Fisher Scientific, Waltham, USA 
Gamma irradiation devices Biobeam 8000, Gamma-Service Medical GmbH, Leipzig, Germany 
Incubator HERAcell 240 CO₂ Incubator, Thermo Fisher, Waltham, USA 
Laminar flow hood Herasafe HS 12, Heraeus, Hanau, Germany 
Microscopes Leica DM IL, Leica, Wetzlar, Germany 
Pipettes (electrical) Easypet 3, Easypet Original, Eppendorf, Hamburg, Germany 
Pipettes (manual) 2.5 µl, 20 µl, 200 µl, 1000 µl Eppendorf Research, Eppendorf, 
Hamburg, Germany 
Software BD FACSDiva 8.0.1, BD Biosciences, Franklin Lakes, USA 
 FlowJo 10.0.7r2, Ashland, USA 
 GraphPad PRISM 7.0, La Jolla, USA 
 Microsoft Office 2010, Redmond, USA 
Vacuum pump Vakuumsytem BVC 21 NT, Vacuubrand, Wertheim, Germany 
Test tube shaker Vortex Genie 3, IKA-Werke, Staufen, Germany 
Water bath 3043, Köttermann, Uetze/Hänigsen, Germany 
1.2 Solutions, media and sera for cell culture 
Albiomin 5 % infusion solution  Biotest, Dreieich, Germany 
human albumin (HSA)  
CliniMACS PBS/EDTA buffer Miltenyi Biotec, Bergisch Gladbach, Germany 
Biocoll separating solution Biochrom, Berlin, Germany 
Brefeldin A Sigma-Aldrich, Steinheim, Germany 
Compensation beads CompBeads Compensation Particles Set, BD Biosciences, San Diego, 
USA 
DMSO  Honeywell, Seelze, Germany 
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Dulbeccos phosphate buffer Gibco, Life Techonologies, Darmstadt, Germany 
saline (PBS)  
FACS clean/rinse/flow BD, Erembodegem, Belgium 
Fix & Perm cell Life Technologies, Frederick, USA 
permeabilization kit  
GM-CSF Sanofi, Bridgewater, USA 
HEPES buffer 1 M Biochrom, Berlin, Germany 
Human AB serum  Human AB serum was kindly provided by Prof. R. Lotfi, University 
 Hospital Ulm, Institute for Transfusion Medicine and German Red 
Cross Blood Services Baden-Württemberg—Hessen, Institute for 
Clinical Transfusion Medicine and Immunogenetics, both from Ulm, 
Germany 
IL-1β, IL-4, IL-6, IL-7, IL-15, CellGro Preclinical Recombinant Human Cytokines, CellGenix, 
TNF-α Freiburg, Germany 
Ionomycin Merck, Darmstadt, Germany 
L-Glutamine 200 mM Biochrom, Berlin, Germany 
Paraformaldehyde (PFA) 4 %, Morphisto GmbH, Frankfurt am Main, Germany 
in PBS, pH 7.4  
PGE2 Sigma-Aldrich, Steinheim, Germany 
Phorbol 12-myristate Merck, Darmstadt, Germany 
13-acetate (PMA)  
Trypan blue Gibco, Life Technologies, Darmstadt, Germany  
VLE RPMI 1640 medium Biochrom, Berlin, Germany 
1.3 Buffers and cell culture medium 
DC medium VLE RPMI 1640 Medium + 
10 % human AB serum + 
1 % HEPES Buffer 1 M + 
1 % L-Glutamine 200 mM 
Freezing medium Human serum albumin (Albiomin 5 % infusion solution) + 
 10 % DMSO 
Staining buffer CliniMACS PBS/EDTA Buffer + 
10 % Human serum albumin (Albiomin 5 % infusion solution; 
end concentration 0.5 % albumin) 
1.4 Consumables 
Blood collection tubes S-Monovette 9ml K3E, Sarstedt, Nümbrecht, Germany 
Cell culture flasks with 25 cm², 75 cm², 175 cm², Sarstedt, Nümbrecht, Germany 
ventilation caps  
Cell culture multiwell plates, Costar Corning Incorporated, New York, USA 
6 well  
Cell culture multiwell plates, Cellstar Greiner Labortechnik, Kremsmünste, Austria 
48 well  
Cell culture multiwell plates, Nunclon Delta Surface, Thermo Fisher Scientific, Waltham, USA 
96 well  
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Compresses Gauze Compresses 10 x 10 cm, Nobamed Paul Danz, Wetter, Germany 
Cover slips Menzel-Gläser 20 x 20 mm, Gerhard Menzel, Braunschweig, Germany 
Freezing tubes Cryo Pure Gefäß 1.8 ml, Sarstedt, Nümbrecht, Germany 
Pasteur pipettes Glass Pasteur Pipettes 230 mm, Brand, Wertheim, Germany 
Pipette tips 0.1 - 2.5 µl, 10 µl, 20 µl, 100 µl, 2 - 200 µl, 1000 µl, Sarstedt, 
Nümbrecht, 
Germany 
Reaction vessels 15 ml, 50 ml Falcon, Corning Science, Tamaulipas, Mexico  
 15 ml, Sarstedt, Nümbrecht, Germany 
 50 ml, Orange Scientific, Braine-l'Alleud, Belgien 
1.5 ml, 2 ml, Eppendorf Safe Lock Tubes, Eppendorf, Hamburg, 
Germany 
Round bottom tubes with cell 5 ml Polystyrene Round Bottom Tube, Falcon, Corning Science, 
strainer snap cap Taumaulipas, Mexico  
Safety gloves Vaso Nitril Blue, B. Braun Melsungen, Melsungen, Germany 
Serological pipettes 2 ml, 25 ml, Costar Stripette, Corning Incorporated, New York, USA 
 5 ml, 10 ml, Serological Pipette, Sarstedt, Nümbrecht, Germany 
Skin disinfectant Cutasept F and Sterilium Classic Pure, Bode Chemie, Hamburg, 
Germany 
Surface disinfectant Ethanol 80 % MEK/Bitrex, CLN, Niederhummel, Germany 
 Bacillol AF, Paul Harmann, Heidenheim, Germany 
1.5 Antibodies 
Fluorochrome Antigen Clone Manufacturer 
APC CD8 SK1 BD Biosciences, Franklin Lakes, USA 
APC CD80 2D10 Biolegend, San Diego, USA 
eFluor 780 Fixable viability dye  eBioscience, ThermoFisher, Waltham, USA 
BB515 CD62L DREG-56 BD Biosciences, Franklin Lakes, USA 
BUV395 CD3 SK7 BD Biosciences, Franklin Lakes, USA 
BV650 CD4 SK3 BD Biosciences, Franklin Lakes, USA 
BV650 CD86 IT2.2 Biolegend, San Diego, USA 
FITC Lineage (CD3, UCHT1, HCD14, Biolegend, San Diego, USA 
CD14, CD19, HIB19, 2H7, 
CD20, CD56) HCD56  
PacificBlue TNF-Α MAb11 Biolegend, San Diego, USA 
PE CD83 HB15e Biolegend, San Diego, USA 
PE IFN-ϒ 25723.11 BD Biosciences, Franklin Lakes, USA 
PE-Cy7 CD45RO UCHL1 Biolegend, San Diego, USA 
PerCP HLA-DR L243 Biolegend, San Diego, USA 
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2 Methods 
2.1 Induction of a mutation-specific de novo immune response 
Each experiment began with the generation of dendritic cells (DCs) and peripheral blood lymphocytes 
(PBLs), included seven cycles of weekly PBL restimulation and finally concluded with a cytokine release 
assay of the stimulated cells (Fig. 4). The whole protocol took 10 weeks and was performed for 18 
different donors. It was kindly provided by Armin Rabsteyn (University Hospital Tübingen / DKFZ 
Heidelberg) and Prof. Dr. Peter Lang (University Hospital Tübingen, General Pediatrics, 
Hematology/Oncology). 
2.1.1 Generation of DCs and PBLs 
All healthy blood donors gave written informed consent prior to blood sampling. Blood samples were 
obtained either by venous punction of 60 – 90 ml EDTA blood or derived from buffy coats kindly provided 
by Prof. Ramin Lotfi (University Hospital Ulm, Institute for Transfusion Medicine and German Red Cross 
Blood Services Baden-Württemberg—Hessen, Institute for Clinical Transfusion Medicine and 
Immunogenetics, Ulm, Germany).  
On day 1, peripheral blood mononuclear cells (PBMCs) were isolated from blood samples via Biocoll 
Fig. 4: Experimental design: Induction of neoantigen-specific de novo T-cell responses. 
On day 1, monocytes/DCs and PBLs were extracted from healthy donors’ PBMCs. Maturation cocktail was added to the DC 
culture on day 8. DC maturity was proved 3 days later via flow cytometry and donors’ PBLs were cocultured with the mature 
DCs loaded with tumor-specific peptide. In a cycle of 7 weekly restimulations, freshly thawed autologous PBMCs were loaded 
with peptide, irradiated and added to the culture in order to restimulate the T cells. Cytokines were added on day +1 and +3 
after restimulation. On day +7 after last restimulation, T cells were stimulated and T-cell responses were measured 14 hours 
later by assessing IFN-γ and TNF-α secretion via flow cytometry. DC = dendritic cell, PBL = peripheral blood lymphocyte, PBMC = 
peripheral blood mononuclear cell  
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density gradient centrifugation:  
The blood sample was diluted 1:2 to 1:4 with phosphate buffered saline (PBS). 35 ml of the diluted 
sample was cautiously layered on 15 ml Biocoll and centrifuged at 800 rcf for 30 minutes without brake. 
The buffy coat was aspirated, washed twice with PBS (500 rcf for 10 minutes, then 250 rcf for 10 minutes) 
and resuspended in DC medium. Cell number and cell viability were assessed (see 2.3.1) and half of the 
cells were frozen for weekly restimulations. The other half was cultured in DC medium at a concentration 
of 5 x 106/ml and incubated in culture flasks (75 cm² when volume ≤ 15 ml, 175 cm² when volume 15 – 35 
ml). After 2 hours, non-adherent cells (PBLs) were centrifuged at 400 rcf for 10 minutes and resuspended 
in DC medium containing 5 ng/ml IL-7. The adherent fraction (monocytes, DCs) was washed three times 
by carefully rinsing with PBS. Fresh DC medium supplemented with IL-4 (40 ng/ml) and GM-CSF 
(100 ng/ml) was added to the adherent cells. Both PBLs and DCs were cultured for 7 days. 
On day 8, DCs were centrifuged at 400 rcf for 6 minutes and resuspended in fresh medium containing IL-
1β (10 ng/ml), IL-4 (40 ng/ml), IL-6 (10 ng/ml), GM-CSF (100 ng/ml), TNF-α (10 ng/ml) and PGE2 
(1000 ng/ml). 
2.1.2 Harvest of DCs, peptide loading and 
coculture of DCs and PBLs 
On day 11, mature DCs were harvested by tapping 
the flask and rinsing it with PBS twice and carefully 
in order not to remove adherent immature cells. 2 
x 106 cells were taken for flow-cytometric analysis 
of DC maturity (see 2.1.3). Mature DCs were 
loaded with tumor-specific peptides and 
cocultured with PBLs: 
Peptides derived from tumor-specific mutations 
were identified as described in C1. Lyophilized 
peptides were diluted in dimethyl sulfoxide 
(DMSO) at a stock concentration of 10 mg/ml and 
further diluted with sterile H2O to a concentration 
of 1 mg/ml. For each condition, mature DCs were 
transferred to a separate 15-ml tube, centrifuged 
at 400 rcf for 6 minutes and resuspended in 
1000 µl DC medium. Peptide was added at a 
concentration of 10 µg/ml and incubated for 2 
hours at 37 °C. Memory-cell controls were 
included by incubating DCs with diluted DMSO 
Table 1: Antibodies for different staining conditions in DC 
maturity proof. 
An isotype control was added to rule out unspecific binding of 
antibodies. An FMO control for PE CD83 was added for better 
assessment of its influence on measurement. DC = dendritic 
cell, FMO = fluorescence minus one 
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(final dilution 1:1000 according to DMSO dilution in peptides) and were treated similarly. Memory-cell 
controls were added in order to reveal already pre-existing memory-cell responses on final intracellular 
cytokine staining (ICS) which were not induced by DC-mediated antigen presentation. 
PBLs were centrifuged at 300 rcf for 10 minutes and resuspended in DC medium at a concentration of 
5 x 106/ml. 
After incubation with either peptide or memory-cell control, DCs were diluted with DC medium to a 
concentration of 0.5 x 106/ml. One ml of both DC and PBL suspension was pipetted into one well of a 24-
well plate and cocultured at 37 °C. 
2.1.3 Maturity proof of DCs 
DCs harvested on day 11 (see 2.1.2) were centrifuged at 400 rcf for 6 minutes and counted. 5 x 105 DCs 
were needed per stain, thus 2 x 106 for conditions “unstained”, “isotype control”, “stained” and “FMO 
CD83”. Isotype control was inserted to exclude unspecific binding. FMO CD83 was used since the CD83 
antigen is considered the most important maturity marker of dendritic cells. 
To block unspecific binding, those cells taken for staining were resuspended in CliniMACS buffer and 10 % 
human AB Serum at a concentration of 2 x 106/ml and incubated on ice for 30 minutes. After washing at 
450 rcf for 4 minutes, 5 x 105 DCs were diluted in a total volume of 50 µl for each condition, with the 
amounts of staining buffer/antibody depicted in Table 1. After 10 minutes of staining at 4 °C, DCs were 
washed twice with staining buffer at 450 rcf for 4 minutes and measured on a BD LSRFortessa Cell 
Analyzer. 
All antibodies were titrated beforehand to determine required concentrations. FITC anti-human lineage 
cocktail antibody consisting of CD3, CD14, CD19, CD20 and CD56 was used to exclude T cells, monocytes, 
macrophages, B cells and NK cells. 
2.1.4 Weekly restimulations with autologous peptide-loaded PBMCs 
Restimulations were performed on day +8, +15, +22, +29, +36, +43 and +50 after coculture. For 
restimulation, autologous PBMCs were used which have been frozen on day 1. Cells were thawed (see 
2.3.2). The pellet was resuspended in 10 ml DC medium and rested overnight in a 25 cm² flask. Approx. 
20 hours later, PBMCs were loaded with peptide: For each condition, PBMCs were transferred to a 15-ml 
tube, centrifuged at 300 rcf for 10 minutes and resuspended in 1000 µl DC medium. Peptide at a 
concentration of 10 µg/ml and diluted DMSO (final dilution 1:1000 according to DMSO dilution in 
peptides) were added to respective tubes. Tubes were incubated for 2 hours at 37 °C and then gamma-
irradiated with 30 Gray in order to prevent cell culture growth. After irradiation, the cell suspension was 
diluted with DC medium to a concentration of 1 x 106 cells/ml. One ml supernatant was removed from 
each well of corresponding DC/PBL coculture plates and filled up with 1 ml peptide-loaded, irradiated 
autologous PBMCs.  
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One and three days after restimulation, 
50 U/ml IL-2 and 10 ng/ml of each IL-7 and 
IL-15 were added. Three days after last 
(7th) restimulation, no cytokines were 
added in order not to influence flow-
cytometric measurements the following 
week. 
2.1.5 Quantification of IFN-γ and TNF-α 
release via flow cytometry 
After 7 restimulations, T cells were 
stimulated with tumor-specific peptide and 
T-cell response was analyzed 14 hours later 
by ICS. Fig. 5 represents different 
conditions: Peptides that were applied to 
DC/PBL/PBMC cocultures during weeks of 
restimulations (column: peptide), 
stimulation solutions applied 14 hours 
prior to final ICS (column: simulation 
condition) and stains included in final ICS 
(column: staining condition). 
Each well of 24-well plates was 
resuspended and 200 µl cell suspension 
was transferred to a 96-well round bottom 
plate. After centrifugation at 300 rcf for 
2 minutes, 100 µl supernatant was 
removed from each well and replaced by 
50 µl of diluted Brefeldin A solution (end 
concentration 10 µg/ml) and 50 µl stimulation solution. Stimulation solution consisted of either the 
positive control containing phorbol-12-myristate-13-acetate (PMA) and Ionomycin (final concentration 
50 ng/ml and 750 ng/ml, respectively), the tumor-specific peptide (final concentration 1 µg/ml) or the 
negative DMSO control (final dilution 1:10000 in analogy to the diluted peptides). The latter served as 
basis for determining the fold change (FC), described in 2.2. 
After 14 hours of incubation at 37 °C, ICS was performed: Cells were transferred to 1.5 ml Eppendorf 
tubes, washed twice at 450 rcf for 4 minutes and resuspended in 100 µl staining buffer containing the 
extracellular staining antibodies indicated in Table 2. The solution was incubated for 15 minutes at room 
temperature (RT). 50 µl Fixation Reagent was added to tubes and incubated for 15 minutes at RT. Cells 
Fig. 5: Conditions of ICS panel. 
For final ICS, cells that had been stimulated with different peptides 
and cells from memory-cell control were used for stimulation 
conditions: Apart from peptide stimulation there was a positive 
PMA/Iono control as well as a negative DMSO control. Peptides X 
and Y stand for arbitrary peptides. FMO = fluorescence minus one, 
DMSO = dimethyl sulfoxide, PMA = phorbol-12-myristate-13-
acetate, Iono = Ionomycin, ICS = intracellular cytokine staining 
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were washed at 450 rcf for 4 minutes and 
pellets were resuspended in 50 µl 
Permeabilization Reagent and the 
intracellular staining antibodies described in 
Table 2. Tubes were incubated for 
30 minutes at RT, then washed at 450 rcf for 
4 minutes, resuspended in 500 µl staining 
buffer and measured on a BD LSRFortessa 
Cell Analyzer. 
2.2 Determination of positive T-cell 
responses 
To examine if mutation-specific peptides are 
capable of inducing T-cell responses, IFN-γ 
and TNF-α secretion values of both T-cell 
groups were required, one being the 
peptide-stimulated (sample) and the other 
the DMSO-stimulated (control) with 
stimulation taking place 14 hours prior to ICS. However, each corresponding pair belonging to those two 
T-cell groups had been treated equally during weeks of 7 restimulations, namely with peptide (for 
determination of de novo T-cell responses) or with DMSO (for memory-cell control). Determined values 
were put into relation to generate the FC. A FC of 1 means that control and sample showed the same 
amount of cytokine release. Whenever the IFN-γ and TNF-α release FC of a specific peptide exceeded 2, 
this particular peptide was considered positive in terms of T-cell response. 
2.3 General cell culture 
Cells were cultured at 37 °C with 5 % CO2. Culture media are indicated in 1.3. 
2.3.1 Counting cells 
Depending on expected cell number, cells were diluted with PBS and then mixed with trypan blue 1:2. 
The suspension was transferred to a Neubauer counting chamber and assessed under the light 
microscope. As trypan blue only stains dead or defect cells, viable cells can be identified in four squares of 
the chamber. Cell concentrations were calculated using the following formula: (determined cell count 
average) x (dilution factor) x 104 = cells/ml. 
2.3.2 Freezing and thawing cells 
For freezing, cells were resuspended in pre-cooled human serum albumin (HSA) supplemented with 10 % 
DMSO at a concentration of up to 6 x 107 cells/1.8 ml and frozen in a freezing container (cooling rate 
Table 2: Antibodies for ICS conditions. 
First, extracellular stain antibodies were added to cells. After 
application of cell fixation and permeabilization reagent, intracellular 
stain antibodies were applied. FMO controls were included. FMO = 
fluorescence minus one, ICS = intracellular cytokine staining 
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1 °C/minute). Vials were transferred to liquid nitrogen cryogenic freezers 24 to 72 h later. When thawing 
cells, they were rapidly warmed up to 37 °C in the water bath and resuspended in warm DC medium. 
They were washed twice at 300 rcf for 10 minutes. 
2.4 Prediction of HLA binding affinity 
In silico databases netMHCpan-2.4 and netMHC-3.0 (115) were consulted to predict binding affinity 
between MHC molecules and potential neoepitopes (mutant peptides). Peptides with a netMHC affinity 
score ≤ 500 nM (corresponds to a logscore of ≥ 0.426) were regarded as binders. Whenever a mutant 
peptide was predicted to bind an HLA type according to the databases while the corresponding wild-type 
peptide did not, the mutant peptide was synthesized and used for the project. 
2.5 Statistics 
Unpaired (Student’s) t-test was applied to examine statistical difference when comparing means of two 
groups. It was performed with GraphPad PRISM 7.0. Significance level was set to a p-value of 0.05; 
designating p < 0.05 (*) significant, p < 0.01 very significant (**) and p < 0.0001 (****) extremely 
significant.
Results 
24 
 
C Results 
1 Preliminary work: Selection and generation of tumor-specific peptides derived from 
medulloblastoma 
The preliminary work for this thesis contained recruitment of tumor samples from two MB patients (Prof. 
Martin Schuhmann, University Clinic Tübingen), identification of neoepitopes by sequencing (Christopher 
Schroeder, Nicolas Casadei and Sven Poths, Institute of Medical Genetics und Applied Genomics, 
Tübingen), binding affinity prediction (Christopher Mohr, Applied Bioinformatics Group, Tübingen) and 
peptide synthesis (Prof. Stefan Stevanović, Department of Immunology at Interfaculty Institute for Cell 
Biology, Tübingen) (Fig. 6). 
1.1 Patients’ characteristics 
The two patients analyzed for this thesis were a female infant (patient 1) and a male juvenile (patient 2), 
Table 3: Characteristics of two pediatric medulloblastoma patients. 
In order to manufacture tumor-specific peptides, neoepitopes had to be detected, originating from tumor tissue, which was 
extracted from two patients with medulloblastoma. Adapted from Blaeschke, Paul et al. (2019) 
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both treated for MB at the Children’s University Clinic of Tübingen. Their characteristics are depicted in 
Table 3. Patient 1 was diagnosed with infratentorial MB and infiltration of the vermis in August 2012 at 
the age of 11 months. Tumor sample was obtained from a biopsy prior to neo-adjuvant chemotherapy 
and tumor resection. Despite ongoing chemotherapeutic treatment, the patient relapsed in April 2014 
with meningeal tumor spreading and underwent resection of relapsed tumor in September 2014. She was 
found in remission at date of last follow-up in September 2016. Patient 2 was diagnosed with anaplastic 
infratentorial MB, infiltrating the cisterna ambiens, and primary temporal metastases on the right side in 
Fig. 6: Workflow: Algorithm for identification of tumor-specific neoantigens. 
Whole-exome NGS was performed to identify tumor-specific mutations. Variants were further analyzed on transcript level by 
RNA NGS. The variants were now filtered by excluding non-detectable (AF < 5 % and/or depth < 20 reads), non-coding, 
synonymous mutations as well as weak HLA binders according to in silico prediction database netMHC. The boxes on the right 
side show how initial amount of patients’ variants was reduced accordingly. The 23 final peptides then result from only 15 
variants due to the fact that some variants could be identified as basis for several HLA-binding epitopes. Due to very rare 
representation of HLA-A*02:11 in German population, 4/23 peptides could not be tested. PBMC = peripheral blood mononuclear 
cell, ctrl. = control, NGS = next generation sequencing, seq = sequencing, AF = allele frequency, HLA = human leucocyte antigen. 
Source: Blaeschke, Paul et al. (2019)  
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January 2014 at the age of 13 years and 8 months. Tumor sample was obtained from tumor resection 
which was performed in January 2014. Chemo- as well as radiotherapy were initiated later the same year. 
However, he experienced relapse in July 2015, underwent surgery but died two months later. Both 
patients’ therapy-naïve tumor tissue and control material (peripheral blood) were cryopreserved.  
1.2 Detection of tumor-specific variants by next generation and deep sequencing 
To identify tumor-specific mutations in resected tumor tissue, next generation sequencing (NGS) of the 
exome was performed. Patient’s PBMCs were used as control tissue. 27 tumor-specific DNA variants were 
detected in patient 1 and 45 in patient 2 (116). Next, all variants were excluded which had an allele 
frequency (AF) lower than 5 % (detection limit) and/or less than 20 reads which resulted in 25 remaining 
variants from patient 1 and 42 from patient 2. AF refers to 
the percentage of reads in which a particular variant can be 
found. Depth means the amount of reads performed on a 
variant. In the next step, variants from non-coding sites or 
which were based on alternative splicing were excluded. 
After that, 11 variants were maintained in patient 1 and 25 in 
patient 2. Eventually, all variants with synonymous mutations 
were excluded since they would not provoke an exchange of 
amino acid. This led to a remaining number of 9 variants in 
patient 1 and 22 in patient 2 (Table 5). At this point, variants’ 
AFs in patient 1 ranged from 5.4 to 34.5 %, most of them 
located slightly above detection limit only, whereas in 
patient 2 they ranged from 25.3 to 62.3 %. Depth performed 
in tumor DNA amounted to approx. 30 – 300 reads in both 
patients.  
In order to examine transcription levels of found mutations, 
RNA NGS of tumor tissue was performed. Criteria of AF and 
depth for detection of an RNA variant were identical as 
described above for DNA variants. Unfortunately, RNA 
quality was poor and only three tumor-specific DNA variants 
were confirmed on RNA level: PDCD10 in patient 1 (AF: 14.9 
%, depth: 47 reads) and INSM1 (AF: 24 %, depth: 25 reads) as 
well as PTEN (AF: 94 %, depth: 18 reads) in patient 2. 
 
Table 4: Detected DNA and RNA variants from NGS 
and deep sequencing. 
Only variants which led to HLA-binding peptides 
are listed. Thresholds defining detected variants 
(marked with x) were allele frequencies of ≥ 5 % 
and coverage of ≥ 20 reads (non-detected 
variants are marked with –). However, MAX gene 
had a low allele frequency in deep sequencing 
(*). Some variants could not be amplified and 
therefore not be sequenced (n/a). RNA 
sequencing was performed to assess expression 
level of variants. NGS = next generation 
sequencing, Seq = sequencing. Adapted from 
Blaeschke, Paul et al. (2019) 
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Table 5: DNA and RNA sequencing data of both next generation and deep sequencing runs. 
Selection of variants in each patient is depicted after exclusion of nonsynonymous mutations and before binding-affinity 
prediction. Detection thresholds are AF ≥ 5 % (0.05) and depth ≥ 20 reads. Abbr. = abbreviated, AF = allele frequency, n/a = not 
applicable, NGS = next generation sequencing. Source: Blaeschke, Paul et al. (2019) 
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Table 6: Characteristics of variants detected by whole exome sequencing in the two patients. 
All variants leading to HLA-binding neoepitopes according to affinity prediction are included. Peptides resulting from MAX and 
PAPD5 (grey frame) could not be tested due to very low allele frequency (0.032 %) of respective HLA type in German population. 
Chromosome number, position on chromosome and base exchange of found mutations are depicted. The function descriptions 
are derived from Uniprot, Entrez Gene, CIViC summary and NCBI databases. HLA = human leucocyte antigen, NCBI = National 
Center for Biotechnology Information. Source: Blaeschke, Paul et al. (2019) 
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Table 7: Function of mutated genes without predicted epitopes. 
For description, see Table 6. The function descriptions are derived from Uniprot, Entrez Gene, CIViC summary and NCBI 
databases. HLA = human leucocyte antigen, NCBI = National Center for Biotechnology Information. Source: Blaeschke, Paul et 
al. (2019) 
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Table 8: Data of in silico binding-affinity predicton of all synthesized mutation-specific peptides. 
Binding affinity was determined by netMHCpan 2.4 database (by netMHC 3.0 when marked with a). Predicted affinity is depicted 
as IC50 value (binding affinity) with a threshold < 500 nM (< 50 nM for strong binders [b]). Logscores are shown (log-transformed 
binding affinity) with a threshold > 0.426. 4/23 peptides could not be tested due to allele frequency of 0.032 % in German 
population of respective HLA type (gray). Nine peptides induced a positive T-cell response (+). Since donor 10 had both HLA-
B*18:01 and -B*44:02, it is unclear, which HLA type mediated response against peptides 9 and 21 (c). HLA = human leucocyte 
antigen, PBMC = peripheral blood mononuclear cell. Source: Blaeschke, Paul et al. (2019) 
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Additional deep sequencing of DNA was performed to confirm the tumor variants found in NGS. 
However, only those 15 variants (3 for patient 1 and 12 for patient 2) yielding HLA-binding peptides 
according to in silico prediction (see 1.3) were included in deep sequencing testing. In patient 1, AFs of 
DNA variants amounted to 2.3 – 11.8 % (depth: approx. 60000 – 84000 reads). In patient 2, they ranged 
from 37.6 – 57.5 % (depth: approx. 11000 – 173000 reads). In sum, 3/3 variants were confirmed in 
patient 1 (however, MAX yielding a low AF) and 11/12 were confirmed in patient 2 (due to poor 
amplification of INSM1; see Table 4).  
To determine the transcriptome with a second method, RNA was transcribed into cDNA, amplified and 
measured by deep sequencing. All 15 variants described above were included. In patient 1, AFs of RNA 
mutants resulted in 2.8 – 9.7 % (depth: approx. 6000 – 22000 reads). Those of patient 2 ranged from 0.1 
– 51.9 % (depth: approx. 12000 – 23000 reads). On RNA level, 3/3 RNA mutants were detected in patient 
1 (with a low AF in MAX-derived transcript) and 6/12 in patient 2. Regarding patient 2, 4/12 variants were 
below detection limit and 2/12 could not be sequenced due to unsuccessful amplification of cDNA (see 
Table 4). 
1.3 Identification of HLA-binding candidates via affinity prediction databases 
In order to find potentially immunogenic neoepitopes from the variants identified in NGS and deep 
sequencing, binders to patients’ HLA types were required. For that purpose, affinity prediction databases 
netMHC was consulted to scan variants for appropriate epitopes. Those had to be MHC class I-binding 
mutant peptides with lengths of 8 to 11 amino acids. Mutant peptides whose corresponding wild-type 
peptides were also predicted as binders were excluded. After these steps, 8 neoepitopes remained from 
patient 1, derived from the 3 variants in the genes MAX, PAPD5 and PDCD10, and 25 neoepitopes from 
patient 2, derived from the 12 variants in the genes ATXN1, HAL, INSM1, LOXHD1, MUC4, NEU2, PCSK9, 
RNF165, SCYL3, SVIL, TSEN54 and VIT. In patient 1, the variants in each gene yielded more than one 
neoepitope and in patient 2, genes leading to several neoepitopes were HAL, PCSK9, RNF165, SCYL3, SVIL 
and VIT. Finally, among all 33 neoepitopes, 23 peptides were synthesized to be tested for 
immunogenicity, 7 deriving from patient 1 and 16 from patient 2 (Table 8). 
Healthy donors were required to carry patients’ HLA types predicted to present the neoepitopes. In 
patient 1, those HLA types were A*02:11, B*52:01 and C*12:02, in patient 2 they were A*01:01, A*25:01, 
B*18:01, B*44:02, C*05:01 and C*12:03. However, due to very low allele frequency of the A*02:11 type 
in the German population, respective peptides could not be tested. A total of 18 healthy donors were 
recruited for the project.  
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2 Induction of neoantigen-specific T-cell responses in vitro 
The following part started with the generation of DCs and PBLs 
derived from healthy donors’ PBMCs and coculture of PBLs with 
mature peptide-pulsed DCs. Then seven weekly restimulations with 
peptide-pulsed and irradiated autologous PBMCs were performed. 
At last, IFN-γ and TNF-α secretion was measured via flow cytometry 
to assess the extent of T-cell response. 
2.1 Flow-cytometric analyses of CD80, CD83 and CD86 indicate 
DC maturity 
DCs, cultivated from donor-isolated PBMCs, served as antigen-
presenting cells (APCs) for induction of de novo T-cell responses. To 
ensure high extent of DCs and DC maturity, surface markers were 
assessed via flow cytometry 72 hours after maturation cocktail (Fig. 
8): HLA-DR+/lineage- cells averaged 92.5 %, representing APCs 
without presence of T cells, monocytes/macrophages, B cells and 
NK cells (116). High amount of CD83+/CD80+ cells (95.2 %) as well as 
CD83+/CD86+ cells (99.7 %) indicated high maturity of DCs (Fig. 7).  
2.2 Successful induction of de novo T-cell responses against 9/19 medulloblastoma-derived peptides 
To assess induction of a de novo T-cell response, ICS was performed eight days after seventh 
restimulation (Fig. 9). 14 hours prior to ICS, cells were stimulated with peptide, DMSO as negative control 
and PMO/Ionomycin as positive control. FC was generated out of negative control and peptide-
stimulated sample. A FC ≥ 2 for either IFN-γ or TNF-α was defined as positive T-cell response. There were 
59 tested peptide/donor combinations in total (Appendix, Table 9), with peptide 21 being tested with six 
donors, peptides 10, 17 and 19 with four donors, peptides 05, 06, 07, 08, 09, 15, 16, 20, 23, 25 and 26 
with three donors and peptides 13, 14, 18 and 24 with two donors (116). Peptide 15 was tested twice 
with the same donor. Moreover, there were two peptides (09 and 21) which had been predicted to bind 
to both HLA B*18:01 and B*44:02. 
Of the 19 mutation-specific peptides tested, there were nine which induced a T-cell response: peptides 5 
and 7 (both derived from PDCD10), 9 (HAL), 15 (NEU2), 16, 19 and 21 (all three derived from PCSK9), 17 
(SVIL) and 25 (TSEN54) (Fig. 10, Fig. 11, Table 8). Peptide 15 was tested a second time 21 weeks after first 
run with a new PBMC sample from the same donor, but a positive T-cell response could not be 
reproduced. 
Three donors (donor 03, 07 and 10) showed more than one positive T-cell response: Donor 03 with 
peptides 05 and 07, donor 07 with peptides 17 and 19 and donor 10 with peptides 09 and 21. 
Fig. 7: High expression of CD80, CD83 and 
CD86 indicated maturity of DCs. 
First, T cells, monocytes, B cells and NK 
cells were excluded by gating on  
HLA-DR+/Lineage- cells. Cells from that 
gate showed high expression of maturity 
markers CD80, CD83 and CD86. Mean 
values ± SD, n = 21. APC = antigen 
presenting cell. Source: Blaeschke, Paul et 
al. (2019) 
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Fig. 9: Example of successfully induced T-cell response (peptide 17) measured by flow cytometry. 
Stimulation was performed 14 hours prior to measurement. Depicted plots are derived from peptide-treated conditions after 
seven restimulations. After exclusion of doublets and dead cells, CD3+ cells were gated. IFN-γ and TNF-α release of CD3+ cells as 
well as of CD4+/CD8+ subsets was assessed and used to generate FCs compared to negative control. FC ≥ 2 was considered a 
positive T-cell response. PMA/Ionomycin (positive) control and FMO controls were included. SSC = side scatter, FSC = forward 
scatter, FMO = fluorescence minus one, PMA = phorbol-12-myristate-13-acetate, Iono = Ionomycin, FC = fold change. Adapted 
from Blaeschke, Paul et al. (2019) 
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2.3 Mutation-specific T-cell responses were mainly caused by CD8+ IFN-γ secreting cells 
Since cytokine release was examined separately for CD3+ and CD4+/CD8+ cells, T-cell responses could be 
assigned not only to IFN-γ and TNF-α secretion, but also to CD3+ cells and CD4+/CD8+ subpopulations (Fig. 
11). One IFN-γ or TNF-α FC value above threshold derived of any of the three groups (CD3+, CD4+ or CD8+) 
was used to define a positive response. 
In all 9/9 positive responses, CD8+ FC values > 2 were found whereas in 2/9 responses CD4+ cells 
produced FC values > 2 (116). IFN-γ secretion above threshold was found in 7/9 and significant secretion 
of TNF-α in 5/9 responses. However, CD3+ gated cells were able to detect only 3/9 responses. Among 
those, IFN-γ accounted for 1/3 and TNF-α for 2/3. 
Fig. 10: 
A) Number of negative and positive tested peptides per donor. Number of tested peptides was dependent on amount of isolated 
donor PBMCs and of number of matching HLA types.  
B) Donor/peptide combinations of all positive tested peptides. Peptide numbers, their amino acid sequence, their predicted 
binding HLA type and the name of the underlying mutated genes from are listed. Since donor 10 had both B*18:01 and B*44:02 
HLA types, it is unclear which one mediated the T-cell response against peptide 9 and 21 (*). PBMC = peripheral blood 
mononuclear cell, HLA = human leucocyte antigen 
B A 
* 
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Regarding the amount of FC values above threshold among cells gated to CD4+ and CD8+, there were a 
total of 14 values, composed of 12/14 CD8+-mediated and 2/14 CD4+-mediated ones. CD8+ cells averaged 
an FC of 3.73 (2.00 – 12.08) and CD4+ cells an FC of 2.13 (2.10 – 2.17). As to the cytokine proportions, 
9/14 values derived from IFN-γ and 5/13 from TNF-α secretion. Mean IFN-γ FC amounted to 2.65 (2.00 – 
3.56) and that of TNF-α to 5.03 (2.00 – 12.08). There were an additional 3 values above threshold, 
derived from CD3+ gated cells. 
Fig. 11: Positive T-cell responses defined by CD3+ cells only or CD4+/CD8+ subpopulations. 
Cytokine release induced by positive tested peptides is depicted as FC compared to negative control. When only considering FCs 
of CD3+ cells, there were a total of three detected positive T-cell responses whereas there were nine when taking into account 
FCs of CD4+/CD8+ subpopulations. Donors, peptide numbers, their amino acid sequence, their predicted binding HLA type and 
the name of the mutated genes from which they were derived are listed. Results from peptide 15 are derived from donor’s first 
PBMC donation (*). FC = fold change, DO = donor. Adapted from Blaeschke, Paul et al. (2019) 
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Fig. 13: Proportion of IFN-γ and TNF-α release of CD4+ and/or CD8+ subpopulation in positive T-cell responses. 
Nine de novo T-cell responses were found, generated by a total of 14 FC values derived from IFN-γ/TNF-α release by CD4+/CD8+ 
cells. By definition, one cytokine secretion FC value of ≥ 2 compared to negative control was sufficient for a positive response. 
IFN-γ-secreting CD8+ cells induced the majority of T-cell responses. Resp. = response, FC = fold change 
Fig. 12: Strong T-cell response against peptide 17 in flow-cytometric analysis. 
Peptide 17 (SVIL) showed the highest TNF-α release FC in CD8+ cells compared to the negative control among all T-cell 
responses with an FC value of 12.08 (0.58/0.048; red frames). Further FCs above threshold were found in CD8+ IFN-γ releasing 
as well as CD3+ TNF-α releasing cells (underlined in red). FC = fold change. Source: Blaeschke, Paul et al. (2019) 
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2.3.1 SVIL-derived peptide 17 induced strongest T-cell response 
When tested with donor 07, peptide 17 (derived from gene SVIL) 
induced a strong T-cell response regarding TNF-α secretion of CD8+ 
cells with an FC of 12.08, generated from frequencies 0.58 (peptide-
stimulated) and 0.048 (negative control) (116). The IFN-γ secretion 
FC of CD8+ cells was 2.75. The CD4+ cell TNF-α FC and CD4+ cell IFN-γ 
FC however did not reach the threshold of 2 (Fig. 12). 
2.4 Impact of T-cell phenotype on induction of mutation-specific 
T-cell responses 
Phenotypes of T cells were examined by implementing antibodies 
labeling CD62L and CD45RO surface markers in ICS. Phenotypes 
were determined as follows (Fig. 14): Naïve/stem cell memory (SCM) cells correspond to CD62L+/CD45RO- 
cells, central memory (CM) cells to CD62L+/CD45RO+, effector memory (EM) cells to CD62L-/CD45RO+ and 
effector cells to CD62L-/CD45RO- cells. 
Fig. 14: Determining T-cell phenotypes. 
SCM = stem cell memory, CM = central 
memory, EM = effector memory. 
Source: Blaeschke, Paul et al. (2019) 
Fig. 15: T-cell differentiation on final ICS. 
T-cell phenotypes on final ICS measurements determined via CD62L and CD45RO. On the left, peptide-stimulated T cells are 
compared. Significant differences were found in naïve/SCM cell amounts. On the right, peptide-stimulated T cells are compared 
to T cells stimulated which PMA/Ionomycin. The latter showed a significant down-regulation of CD62L, resulting in decreased 
amount of naïve/SCM and CM cells. Mean values ± SD. * p < 0.05, **** p < 0.0001. PMA = phorbol-12-myristate-13-acetate, Iono 
= Ionomycin, SCM = stem cell memory, CM = central memory, EM = effector memory. Adapted from Blaeschke, Paul et al. (2019) 
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When pooling all values derived from negative and positive tested peptides, naïve/SCM cell proportions 
showed significant differences (Fig. 15, left): They amounted for 23.03 % of all phenotypes in conditions 
with negative tested peptide as compared with 15.32 % in those with positive tested peptide (116). To 
assess stimulation capacity of T cells, different conditions were stimulated with positive control 
PMA/Ionomycin 14 hours prior to ICS. In all measurements, a down-regulation of CD62L could be 
observed (Fig. 15, right). 
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D Discussion 
Medulloblastoma is the most common malignant pediatric brain tumor (117). Treatment is challenging 
and is accompanied by long-term side effects affecting the developing child. Therefore, new therapeutic 
approaches are needed. The aim of the present study was to investigate the immunogenicity of tumor-
specific peptides derived from two pediatric MB patients. DCs and lymphocytes were gained from healthy 
donors’ PBMCs, the lymphocytes cocultivated with peptide-pulsed DCs and finally induction of a de novo 
T-cell response was measured via IFN-γ and TNF-α release. Nine of nineteen peptides were able to induce 
T-cell responses. The results indicate that MB tissue harbors immunogenic epitopes that can potentially 
serve as targets for immunotherapy. This paves the way for further studies that can lead to therapeutic 
application in the clinic: One potential future approach being peptide vaccination where tumor-specific 
peptides are synthesized and administered to boost the endogenous immune response. ATT is another 
highly individualized future treatment option: At first, it would require the identification of a tumor-
reactive TCR in a positive T-cell response. This TCR could then be sequenced, cloned and transduced into 
T cells which would be re-administered to the patient. 
1 “Reverse immunology” for identification of tumor-specific neoepitopes 
The neoepitopes in this project were acquired by “reverse immunology” (118): By whole exome 
sequencing of freshly isolated tumor and healthy (control) tissue from two MB patients, somatic 
mutations in the tumors were identified. Patients’ PBMCs served as tumor-matching controls which is 
appropriate for non-hematologic cancer entities (119). Within the detected variants, HLA-binding 
peptides containing the mutations were determined in silico. This concept allows identifying a large 
antigen reservoir since it takes all neoepitopes into account that could potentially be derived from genes 
with tumor-specific mutations. However, it is not equally reliable compared to direct epitope 
acquirement methods as it cannot consider all steps between the transcription of a mutation and the 
expression of its analogous antigen. For instance, discrepancy between in silico and in vivo neoepitopes 
can occur as proteasomal cleavage can destroy antigens (120) and predicting MHC binding of peptides 
containing cysteine has shown to be problematic (121). In order to verify the variants identified by whole 
exome sequencing, deep sequencing of amplified DNA was performed. It achieved a mean depth of 
> 45000 reads and confirmed 93 % of the variants. 
Determining suitable cancer neoepitopes is often performed with a focus on MHC class I-binding antigens 
and therefore on the CD8+ T-cell axis (122, 123), further discussed in 3. Accordingly, selection of 
neoepitopes for this project was made exclusively using MHC class I-binding affinity prediction. The 
databases consulted for this purpose use algorithms based on experimental knowledge of proteasomal 
cleavage, peptide transport to the endoplasmic reticulum and MHC binding (124). A cut-off of 500 nM in 
terms of netMHC affinity score was applied. Although Paul et al. recently showed that each HLA allele has 
unique binding affinities to its epitopes and therefore different thresholds, the value of 500 nM is 
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commonly used and a suitable universal threshold (125). Peptides with an affinity of ≤ 50 nM were 
considered strong binders. Only PAPD5 and PCSK9 peptides were predicted strong binders. However, 
PAPD5 could not be tested due to very low allele frequency (0.032 %) of respective HLA type in German 
population. A T-cell response could be induced against the PCSK9 peptide. Otherwise we could not 
observe a correlation between predicted affinity and T-cell response. However, regarding ATT, Engels et 
al. showed the significance of high affinity of peptides for MHC molecules (126): Only high-affinity 
peptide-MHC interactions resulted in effective tumor eradication by T cells.   
Peptide length was set to be between 8 and 11 amino acids. This corresponds to the range of epitope 
lengths commonly binding to MHC class I molecules, which is 8 – 10 amino acids (10). The MHC class I 
molecule’s antigen-binding groove is closed at each end and restricts binding to short and specific 
peptides with conserved anchor residues. Most of those MHC molecules have a strong preference for 
binding nonamer peptides (127). This implies, however, that there is a considerable bias towards 
peptides of said length, since more than 73 % of the database-underlying data apply to nonamers (127). 
That leads to impaired accuracy of peptide binding affinities containing more or less than nine amino 
acids. On the other hand, MHC class II molecules are open at both ends, allowing peptides to bind with an 
approximate length of 11 to 30 amino acids (11). Kreiter et al., who found high amounts of immunogenic 
neoepitopes in murine tumor models using 27mer peptides, suggest this was due to the less strict 
conditions required for peptide-binding to MHC class II molecules (128). 
Not only is the peptides’ length critical for MHC binding: HLA-B type has demonstrated to bind a more 
diverse repertoire of self-peptides, derived from a larger amount of source proteins (129). Schellens et al. 
argue that the HLA-B molecules might therefore have an increased chance of presenting 
immunodominant peptides and be associated with immune responses more often (129). Furthermore, 
HLA-B might have a superior impact on the outcome of various infectious diseases, inflammatory 
conditions but also malignancies compared to HLA-A (129). 
A mutant HLA-binding neoepitope was only selected whenever its wild-type counterpart was not 
predicted to bind to the HLA type. Binding properties especially depend on amino acids located in the 
anchor positions within the MHC-binding groove (130). It has been shown that peptides derived from     
mutations—therefore referred to as facilitating mutations—may be more effective in eliciting specific T-
cell responses than their wild-type equivalent due to higher binding affinity of the mutant peptide (122, 
131). This is due to competition between mutant and wild-type peptide in terms of binding to the MHC 
molecule in the endoplasmic reticulum and endosomes. 
In order to determine to which extend DNA variants were detectable on transcriptome level, RNA from 
the tumor samples was analyzed by whole exome sequencing. To verify the findings, RNA was transcribed 
into cDNA, amplified and measured by deep sequencing. In whole exome sequencing, a total of 3 variants 
were verified on RNA level whereas in deep sequencing 9/15 variants could be confirmed. This relatively 
small amount of expressed mutations is in line with the findings of Jones et al. They found 48 % of non-
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synonymous mutations represented on RNA level concluding that only very few driving hits are required 
to generate MB (104). Since mRNAs have a short lifetime they might not genuinely represent expression 
in vivo. In addition, Cohen et al. were able to induce neoepitopes-specific T-cell responses based on 
whole exome sequencing data only (119). For both reasons, variants not detectable on RNA level were 
nevertheless included into the testing. 
2 DCs are crucial for de novo T-cell responses and for immune regulation 
DCs are the essential APCs regarding the induction of de novo T-cell responses. As classical professional 
APCs, constitutively expressing MHC class II molecules, they localize to secondary lymphoid organs in 
order to prime naïve CD4+ T cells (132). However, via cross-presentation they interact with and promote 
CD8+ cells by presenting them (tumor) antigen on their MHC class I receptors (133). Thus, DCs induce 
rapid activation of tissue-resident memory CD8+ T cells upon re-infection (134). In this project, DCs were 
generated in vitro from monocytes originating from healthy donors’ PBCMs, achieving a maturity of > 
92 %. Those monocyte-derived DCs (mo-DCs) also constitute the major proportion among DCs during 
inflammation and therefore in the inflammatory environment of tumors (135). Tang-Huau et al. recently 
showed that both mo-DCs obtained from human ascites and generated in vitro from monocytes are 
efficient at cross-presentation (135). In a murine experiment, Kuhn et al. reported that mo-DCs isolated 
by depleting other CD11c+ cells are sufficient for induction of tumor-specific CD8+ T cell responses and 
successful tumor immunity (136). 
In addition, DCs are critical for immune homeostasis and thus for prevention of overactivity and 
autoimmunity. They induce the differentiation of CD4+FOXP3+ regulatory T cells (Tregs), a T-cell subset 
essential for peripheral tolerance and important for tumor escape. The tolerogenic effect of DCs is also 
promoted by the tumor microenvironment: Vascular endothelial growth factor (VEGF) is released by 
tumors and has suppressive effect on dendritic cell differentiation (137). In addition, IL-6 and macrophage 
colony-stimulating factor (M-CSF), which are produced by tumors, suppress monocyte-induced 
differentiation toward DCs (138). 
3 CD4+ and CD8+ T cells play ambiguous roles in eliciting T-cell responses 
In the final ICS measurement, cytokine release was assessed to define positive T-cell responses. Since 
epitope-binding affinity was predicted for MHC class I molecules, responses of CD8+ T cells were the main 
focus. As expected, CD8+ was the dominant T-cell subset, secreting cytokines above threshold in all 9/9 
final elicited responses. CD4+ cells, however, were positive in 2/9 responses. The majority of responses 
was mediated by IFN-γ. 
Concerning the proportional contribution of CD4+ and CD8+ T cells in mounting an effective immune 
response, notions differ considerably. One established hypothesis says that CD4+ T cell help is needed for 
the differentiation of cytotoxic CD8+ T cells (139-141) and a successful and long-lasting CD8 immune 
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response (142). Naïve CD4+ cells are differentiated along the Type 1 helper T cell (Th1) subset which is the 
most favorable one for tumor control (143). This process is mediated by IL-12 which is released by DCs 
upon antigen presentation. Th1 cells enhance the development of CD8+ cells through epitope spreading. 
They promote DCs via the CD40 receptor and thus activate CTLs via cross-priming and cross-presentation 
(144). IFN-γ is secreted which further amplifies Th1-cell development and has a direct toxic effect on 
tumor cells (145). 
However, CD8 responses can be robust without CD4 help. While CD8+ cells in the absence of CD4+ T cells 
can be impaired during viral or bacterial infections (146, 147), the absence of CD4+ cells may even 
improve CTL-mediated cancer control: After complete ablation of CD4+ helper cells in a murine melanoma 
mouse model, Côté et al. could not observe impaired development of an antitumor memory CD8 
response (148). They even reported increased count of CD8+ cells as well as IFN-γ production possibly due 
to Treg ablation.  
On the other hand, recent findings indicate a dominance of CD4+ T cells: Kreiter et al. suggest that 
antitumor activity might rather be conferred by CD4+ than CD8+ T cells (128). In three independent 
murine tumor models they showed immunogenicity of numerous tumor-specific antigens. The tumor 
entities comprised melanoma, colon carcinoma and breast cancer. Analyzing the involved T-cell subsets, 
they found CD4+ cells to be responsible for most of the T-cell responses in all three tumor models. The 
essential role of CD4+ cells and MHC class II-associated epitopes was also demonstrated by Tran et al. 
They found neoepitope-specific CD4+ Th1 cells among TILs in metastatic cholangiocarcinoma patients. 
Upon expansion and re-administration of those cells to the patients they could achieve tumor regression 
(30). 
In this project, only CD8+ T cells were taken into account for eliciting T-cell responses by exclusively 
considering the healthy donors’ MHC class I molecules. This is because of the major difference between 
existing in silico prediction tools for epitope-binding of MHC class I and II: Methods to predict MHC class I-
restricted peptide binding have higher performance compared to MHC class II (149). This is due to several 
reasons: MHC class II molecules are highly polymorphic (150) and MHC class II-binding peptides have 
variable lengths due to the MHC molecule’s open binding groove at both ends (151). 
4 Several immunogenic peptides are derived from genes with potential impact on tumorigenesis 
Tumor samples were taken from two patients suffering from MB. In both cases it was high risk MB 
including either young age (patient 1) or primary metastasis (patient 2). MB is a cancer entity of minimal 
mutational load (29). Analysis of 92 MB cases in a study yielded a mutation rate of 0.35 non-silent 
mutations per megabase (106). This contrasts with high immunogenic tumors in adults such as malignant 
melanoma, which shows a mean of > 10 mutations per megabase (29). Generally, mutational burden in 
tumors is known to increase significantly with age (152). In line with this, Jones et al. found a positive 
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correlation between patient age and mutation rate (104). Both findings are consistent with the higher 
amount of variants found in patient 2 in the present project.  
In this project we analyzed the detected mutations in terms of their potential influence in tumor 
formation and growth. Since samples were taken before chemo- or radiation therapy, the mutations 
found in the tumor were not induced by therapeutic intervention. MB shows strong genetic 
heterogeneity with most mutated genes only appearing in single cases (104), as was observed in this 
project. In contrast, in pediatric glioblastoma frequently recurring hotspot mutations have been identified 
(104). However, there are some known mutated genes described in MB such as CTNNB1, PTCH1, MLL2, 
SMARCA4 and TP53 (104, 106). 
For patient 1, a tumor-specific mutation in Programmed Cell Death 10 (PDCD10) was detected. 
Highlighting its function is particularly interesting as two peptides derived from this variant induced a 
specific T-cell response. PDCD10 encodes a highly conserved protein associated with cell proliferation and 
apoptosis (153). Its crucial role in apoptosis was shown by Chen et al.: When overexpressed in a cell line 
by transfection, respective cells showed increased apoptosis via caspase-3 activation (153). Consequently, 
overexpressed PDCD10 containing a point mutation resulted in reduced cell loss compared to the 
PDCD10 wild type (153).  Moreover, Lauenborg et al. described the constitutive expression of PDCD10 in 
malignant T cells, found in cutaneous T cell lymphoma (154). However, they reported a relatively high 
expression in non-malignant T cells as well, in this case protecting them against apoptosis and promoting 
cell proliferation. Another critical function of PDCD10 concerns vascular development: He et al. reported 
that PDCD10 stabilizes the vascular endothelial growth factor receptor 2 (VEGFR2) in response to 
stimulation by VEGF (155). Mice lacking a normal PDCD10 gene died at embryonic stage due to defects in 
angiogenesis. In addition, mutants of PDCD10 in human patients were equally unable to stabilize VEGFR2 
which facilitated its endocytosis and resulted in signaling defects. In consistence with this role, mutations 
in PDCD10 are associated with cerebral cavernous malformations (156). 
In patient 2, all three peptides derived from Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) 
induced a positive T-cell response. Its encoded protein plays a role in the regulation of low-density 
lipoprotein (LDL) receptors (157). Mutations in PCSK9 are consequently associated with disorder in 
cholesterol and fatty acid metabolism. This gene has not yet been described in tumorigenesis of MB 
although it has been associated with an anti-apoptotic effect in a study by Xu et al. When transfecting 
PCSK9 small interfering (si)RNA into a lung cancer cell line, they observed increased induction of 
apoptosis and therefore anti-tumor acitivity (158). 
Mutations were moreover found in the genes Phosphatidylinisitol-4,5-Bisphosphate-3-Kinase Catalytic 
Subunit Alpha (PIK3CA) and Phosphatase And Tensin Homolog (PTEN) in patient 2. Neither resulted in 
neoepitopes predicted to bind MHC class I, but both are well-known in tumorigenesis: The PI3K/Akt 
signaling pathway with its PIK3CA-derived protein phosphoinositide 3-kinase (PI3K) is involved in the 
development of several tumor entities. It is the most recurrently enhanced pathway in breast cancer 
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(159). Additionally, PI3K mutations were found in other malignancies such as lung and colorectal cancer 
(160, 161) but also in a variety of brain tumors including pediatric MB (162). Overexpression of the p110α 
protein, the catalytic subunit of PI3K, was described in MB tumors and cell lines (163). Moreover, the 
PI3K/Akt pathway has a well-described impact in disorders that concern brain overgrowth (164). It might 
also have an important role in physiological brain growth (165). PTEN, on the other hand, is a tumor 
suppressor gene and its gene products repress the PI3K/Akt pathway. It is frequently mutated in cancer 
which results in loss-of-function and consecutive increased cell growth, proliferation, and survival (166).   
In addition, a mucin 4 (MUC4) mutation was detected in patient 2. MUC4 is associated with cell 
proliferation and inhibition of apoptosis (167). It plays a role in several cancer entities such as ovarian, 
pancreatic and breast cancer (168-170). However, its impact in MB has not yet been described.  
5 Future therapeutic approaches include peptide vaccination and adoptive T-cell transfer 
Immunotherapeutic approaches including immune checkpoint inhibition, adoptive T-cell transfer and 
peptide vaccines have revolutionized cancer treatment. However, in MB, immunotherapeutic approaches 
could not yet achieve as convincing results as in non-pediatric high immunogenic tumors such as 
malignant melanoma where immunotherapy was introduced decades ago (77). A promising study 
involving ATT in lymphodepleted medulloblastoma mice showed tumor regression without any 
neurological dysfunction upon infusion of TILs which were activated ex vivo before administration (171). 
Naturally occurring TILs are critical for antitumor response and associated with a better outcome in 
several tumor entities, such as melanoma (172) and ovarian carcinoma (38). TILs have been identified in 
pediatric patients with MB (173). Analyzing the T-cell subsets, CD8+ cells constituted the main proportion 
(52 %) followed by CD4+ cells (35 %) and Tregs (2.5 %). However, no association between frequency of 
TILs and patients survival was observed (173). 
In this project we showed feasibility of an individualized approach to detect immunogenic patient-specific 
neoepitopes, which can potentially be harnessed for immunotherapy. In a next step, the neoepitope-
reactive TCRs could be identified in order to engineer transgenic T cells for ATT. In addition, immunogenic 
peptides could be synthesized and administered to the patient to boost endogenous antitumor response. 
In adoptive T cell therapy, T cells are administered to patients to help eradicate malignant tumors. The 
infused cells can either be unaltered TILs or genetically modified T cells expressing specific TCRs or CARs 
(83). Whereas early ATT approaches exclusively used unmodified TILs, which additionally required time-
consuming expansion and selection processes ex vivo (174), now highly specific transgene T cells are 
engineered: Peripheral blood lymphocytes are transduced with tumor-reactive TCRs that target cancer 
cells in tumor entities such as melanoma, which is currently being evaluated in different trials (175). The 
efficacy of T cells to eliminate cells has recently been shown by Leisegang et al. (27). They were able to 
eradicate a large solid tumor by TCR-engineered T cells targeting only one single cancer-specific point 
mutation. Despite successful tumor elimination, relapse was observed which occurred due to therapy-
Discussion 
47 
 
induced selection of escape variants. Those variants were able to escape immune attack by down-
regulation or total lack of antigen-expression. Transduction of the mutant gene into similar tumor cells 
could successfully reproduce tumor elimination. 
According to this study, it might be inevitable to target multiple independent neoepitopes on the same 
tumor to reach long-lasting tumor control (27) and reduce selection of escape variants. Consequently, in 
tumors such as MB, heterogeneity can contribute to low allele frequencies and thus lead to decreased 
antitumor response. Therefore, targeting a variety of neoepitopes might be essential for successful tumor 
elimination. Moreover, mutational burden has an influence on immunotherapeutic effects: In a recent 
study, immune checkpoint blockade yielded higher response rates in tumors with high mutational 
burden, especially examined among melanoma and non–small cell lung cancer (NSCLC) (176). However, 
when combining blockade of several checkpoints, this correlation was not observed. In fact, another 
study analyzing immune checkpoint blockade of NSCLC adenocarcinoma detected that a combination of 
high mutational burden and low neoantigen intratumor heterogeneity led to longer survival rates than 
either variable alone (177). 
Peptide vaccination aims at inducing an endogenous immune response via administration of tumor 
antigens (178). It has successfully been applied in different settings: In patients with pancreatic or 
colorectal cancer, a mutant ras peptide was administered leading to specific T-cell responses and 
increased overall survival in the responders (179). In glioblastoma patients with total tumor resection and 
chemoradiation, a vaccine was used which consisted of the mutated epidermal growth factor receptor 
variant III. It was administered in addition to adjuvant temozolomide and resulted in improvement of 
progression-free and overall survival (180). 
Epitope loss can be challenging not only for adoptive T-cell transfer but also for peptide vaccination, 
partly due to deficiency in the antigen processing machinery (181). To solve this problem, the generation 
of multi-epitope vaccines has been proposed to increase breadth and diversity of neoantigen-specific T 
cells and to include MHC class II-restricted peptides to involve CD4+ responses (67, 182, 183). Vaccination 
with long peptides has proven to induce a stronger immune response, implying a delayed but sustained 
CTL response (184). This may be due to the necessary processing of long peptides by APCs compared to 
short peptides that elicit a CD8+ T cell response only (185). Another issue of peptide vaccines, observed in 
several cases, is their potential to induce peripheral T-cell tolerance and even tumor progression (68, 
186). T-cell tolerance can be caused by systemical antigen application and subsequent presentation by 
non-professional APCs lacking costimulatory signals (187). In addition, changes regarding the 
administration of peptides have shown to be crucial for the immune response, either leading to T-cell 
induction or rendering T cells unresponsive. These changes imply the amount of antigen, route and 
frequency of application and the used adjuvant (188). Another critical factor with effect on the immune 
response are the peptide’s chemical properties: Amphiphilic epitopes have proven higher 
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immunogenicity than their non-amphiphilic counterparts (189, 190). Due to mentioned factors, peptide-
based vaccines have to be employed with caution in a human setting (68). 
5.1 Impact of T-cell subsets and differentiation in ATT 
T cells undergo differentiation, comprising the following subsets in their development: naïve, stem cell 
memory (SCM), central memory (CM), effector memory (EM) and finally effector cells. Although later 
phenotypes are associated with increased production of target-eliminating molecules like granzymes and 
IFN-γ, proliferation potential and antitumor efficacy declines along the differentiation process (191). 
Accordingly, CD8+ cells have shown to decrease in survival and proliferation capacity the more they are 
stimulated with IL-2 and their specific antigen (43). This paradox might be explained by the loss of the 
ability to produce IL-2, to home to lymph nodes and to resist apoptotic death along the differentiation 
process (43). Sommermeyer et al. showed that T-cell subsets as well as differentiation have an impact on 
antitumor effect in CD19-directed CAR T-cell therapy (192): When targeting disseminated lymphoma in 
murine models, superior efficacy among CD4+ cells was observed in samples derived from naïve and CM 
subsets. Using CD8+ cells in the same model, the strongest antitumor efficacy was detected in CM cell-
derived samples. In the same study examining CAR T cells they concluded that CD4+ T cells support 
enhanced CD8+ T-cell proliferation. Notably, the combination of CD8+ CM-derived cells with CD4+ cells 
from either the naïve or CM subset conferred the strongest antitumor activity (95). 
In the present project, phenotyping of the T cells was included in final ICS measurement, reflecting T-cell 
differentiation after seven restimulations. Surface markers CD45RO and CD62L (L-selectin) were 
measured to assess phenotypes. Using this panel, distinction between naïve and SCM T cells is not 
possible. When comparing T cells that induced a peptide-specific response (Tpos), and those that did not 
(Tneg), naïve/SCM cell proportion was the only one significantly different: naïve/SCM cells averaged 
23.03 % in Tpos compared to 15.32 % in Tneg. Moreover, positive control in final ICS measurement was 
realized by PMA/Ionomycin flow-cytometric stain. Naïve/SCM and CM cell proportion combined 
amounted to 7.12 %, implying a down-regulation of L-selectin during 14 hours of stimulation, which is 
consistent with its properties: L-selectin is a cell adhesion molecule on leukocytes, responsible for their 
homing to lymph nodes and migration to inflammation sites (193, 194). This is mediated through 
tethering and rolling of the leukocytes on the endothelium. Upon activation, L-selectin is rapidly shed 
from the surface of leukocytes (195). Down-regulation of L-selectin is also induced by chemoattractants 
such as PMA (196).  
6 Conclusion and outlook 
In conclusion, we have demonstrated in a “proof a concept” approach with pediatric medulloblastoma 
that immunogenicity of tumor-specific neoantigens can be detected even against tumors with low 
mutational burden. Identification of neoantigens was accomplished through DNA and RNA sequencing 
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technologies and computational affinity prediction. Mutation-specific T-cell responses were determined 
via flow-cytometric measurement of IFN-γ and TNF-α and were found against 9/19 mutant peptides. 
In this project, unbiased PBMC-derived DCs and PBLs from healthy donors were used. Strønen et al found 
that such naïve T cells can specifically respond to neoepitopes that had been neglected by autologous 
patient T cells (49). Further trials including patient T cells would be useful to examine to what extent they 
are reactive to tumor-specific neoepitopes. Those cells are often impaired and driven to exhaustion as a 
result of constant tumor-mediated inflammatory setting and antigen exposure (197). However, 
autologous TILs can mediate durable responses in patients with metastatic melanoma (174). 
Mutated tumor-specific epitopes are a promising target for immunotherapy: As they have not undergone 
central tolerance mechanisms they are prone to be recognized as non-self antigens. Due to their 
exclusive expression on the tumor, risk for autoimmunity is reduced. Identification of immunogenic 
neoantigens paves the path for personalized therapeutic strategies such as peptide vaccination and 
adoptive T-cell transfer in pediatric patients with advanced medulloblastoma. 
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E Summary 
Medulloblastoma is the most common malignant brain tumor in childhood and adolescence and 
constitutes an important cause for cancer-related death in pediatric patients. Although standard therapy 
including surgery, chemotherapy and radiation can cure up to 80 % of average-risk patients, they imply 
severe cognitive long-term adverse effects and are unsatisfactory in advanced tumors. Therefore, 
alternative treatment strategies need to be established. Immunotherapeutic approaches like peptide 
vaccination and adoptive T-cell transfer (ATT) aim at enhancing self-protection through detection and 
elimination of malignant cells. Tumor-specific neoepitopes are promising targets for ATT as they are 
expressed exclusively by cancer tissue. Moreover, administration of mutation-derived peptide vaccines 
allows augmenting the endogenous immune response through abundant presentation of tumor antigen. 
In this proof-of-concept study we demonstrate a highly individualized approach where patient-specific 
neoepitopes are determined and tested for immunogenicity.  
Primary tumor samples from two pediatric medulloblastoma patients were analyzed in this project. 
Tumor-specific mutations were identified by next generation sequencing of tumor tissue and whole 
blood. Variants were confirmed by deep sequencing. In order to identify neoepitope peptides presented 
by the patients’ human leucocyte antigen (HLA) molecules, HLA binding affinity was predicted in silico by 
netMHC database. Respective peptides were synthesized and blood cells from healthy donors matching 
the patients’ HLA types were used to provide T lymphocytes and dendritic cells for antigen presentation. 
After seven restimulations in vitro, CD8+ cytotoxic T-cell reactivity against neoepitopes was assessed via 
flow-cytometric analysis of Interferon gamma and Tumor Necrosis Factor alpha release. A successful de 
novo T-cell response was induced for 9 of 19 tested peptides. 
In this proof-of-principle study we show that induction of a T-cell response against medullobastoma-
derived neoantigens is feasible despite low mutational burden and low immunogenicity. In the future, 
this strategy can be used to synthesize individualized peptide cocktails for peptide vaccination or identify 
medulloblastoma-specific T-cell receptors for ATT. Long-term aims of this study are the identification of 
medulloblastoma/T-cell interaction and improvement of current treatment options for pediatric patients 
with advanced medulloblastoma. 
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E Zusammenfassung 
Medulloblastom ist der häufigste bösartige Hirntumor im Kindes- und Jugendalter und bedeutend 
beteiligt an krebsassoziierten Todesfällen in pädiatrischen Patienten. Obwohl Standardtherapien, 
bestehend aus Operation, Chemotherapie und Bestrahlung, bis zu 80 % der Patienten mit 
durchschnittlichem Risiko heilen können, verursachen sie schwere kognitive Langzeitfolgen und wirken in 
fortgeschrittenen Tumorstadien unbefriedigend. Daher müssen alternative Behandlungsstrategien 
etabliert werden. Immuntherapeutische Ansätze wie Peptidvakzinierung und adoptiver T-Zell-Transfer 
(ATT) zielen darauf ab, die Mittel des Körpers zur Erkennung und Elimination von malignen Zellen zu 
steigern. Tumorspezifische Neoepitope sind vielversprechende Targets für ATT, da sie ausschließlich vom 
Tumorgewebe exprimiert werden. Weiterhin erlaubt die Verabreichung von mutationsbasierten 
Peptidvakzinen eine Zunahme der endogenen Immunantwort durch vielfache Tumorantigen-
Präsentation. In dieser Machbarkeitsstudie zeigen wir eine vollkommen individualisierte Vorgehensweise, 
mit der patientenspezifische Neoepitope ermittelt und auf Immunogenität getestet werden.  
Primärtumor-Proben von zwei pädiatrischen Medulloblastom-Patienten wurden in diesem Projekt 
eingesetzt. Tumorspezifische Mutationen wurden durch Next Generation Sequencing von Tumorgewebe 
und Blutzellen identifiziert. Die Varianten wurden durch Deep Sequencing bestätigt. Um Neoepitope zu 
ermitteln, deren Präsentation durch die humanen Leukozytenantigen-Moleküle (HLA) der Patienten 
angenommen werden konnte, wurde die HLA-Bindungsaffinität durch die netMHC-Datenbank in silico 
vorausgesagt und die so bestimmten Peptide synthetisiert. Blutzellen von gesunden Spendern, deren 
HLA-Typen denen der Patienten entsprachen, wurden für die Bereitstellung von T-Lymphozyten und 
dendritischen Zellen zur Antigenpräsentation verwendet. Nach sieben Restimulationen in vitro wurde die 
Reaktivität von zytotoxischen CD8+ T-Zellen gegen die Neoepitope anhand der durchflusszytometrisch 
bestimmten Ausschüttung von Interferon-gamma und Tumornekrosefaktor-alpha untersucht. Eine 
erfolgreiche de novo T-Zell-Antwort wurde für 9 von 19 getesteten Peptiden induziert. 
In dieser Machbarkeitsstudie zeigen wir, dass die Induktion einer T-Zell-Antwort gegen Medulloblastom-
assoziierte Neoepitope trotz niedriger Mutationslast und Immunogenität möglich ist. Zukünftig kann 
dieser Ansatz genutzt werden, um individualisierte Peptidcocktails für Peptidvakzinierung herzustellen 
oder Medulloblastom-spezifische T-Zell-Rezeptoren für ATT zu ermitteln. Langfristige Ziele dieser Studie 
sind die Bestimmung der Medulloblastom/T-Zell-Interaktion und die Verbesserung der aktuellen 
Behandlungsoptionen für pädiatrische Patienten mit fortgeschrittenem Medulloblastom. 
 
 
52 
 
F References 
1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. 
2. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001;357(9270):1777-89. 
3. Strutt TM, McKinstry KK, Dibble JP, Winchell C, Kuang Y, Curtis JD, et al. Memory CD4+ T cells 
induce innate responses independently of pathogen. Nat Med. 2010;16(5):558-64, 1p following 64. 
4. Schwartz MA, Kolhatkar NS, Thouvenel C, Khim S, Rawlings DJ. CD4+ T cells and CD40 participate in 
selection and homeostasis of peripheral B cells. J Immunol. 2014;193(7):3492-502. 
5. Beuneu H, Garcia Z, Bousso P. Cutting edge: cognate CD4 help promotes recruitment of antigen-
specific CD8 T cells around dendritic cells. J Immunol. 2006;177(3):1406-10. 
6. Luckheeram RV, Zhou R, Verma AD, Xia B. CD4(+)T cells: differentiation and functions. Clin Dev 
Immunol. 2012;2012:925135. 
7. Hewitt EW. The MHC class I antigen presentation pathway: strategies for viral immune evasion. 
Immunology. 2003;110(2):163-9. 
8. Ting JP, Trowsdale J. Genetic control of MHC class II expression. Cell. 2002;109 Suppl:S21-33. 
9. Rammensee HG, Falk K, Rotzschke O. Peptides naturally presented by MHC class I molecules. Annu 
Rev Immunol. 1993;11:213-44. 
10. Bouvier M, Wiley DC. Importance of peptide amino and carboxyl termini to the stability of MHC 
class I molecules. Science. 1994;265(5170):398-402. 
11. Rammensee HG, Friede T, Stevanoviic S. MHC ligands and peptide motifs: first listing. 
Immunogenetics. 1995;41(4):178-228. 
12. Lurquin C, Van Pel A, Mariame B, De Plaen E, Szikora JP, Janssens C, et al. Structure of the gene of 
tum- transplantation antigen P91A: the mutated exon encodes a peptide recognized with Ld by 
cytolytic T cells. Cell. 1989;58(2):293-303. 
13. Kawashima I, Tsai V, Southwood S, Takesako K, Sette A, Celis E. Identification of HLA-A3-restricted 
cytotoxic T lymphocyte epitopes from carcinoembryonic antigen and HER-2/neu by primary in vitro 
immunization with peptide-pulsed dendritic cells. Cancer Res. 1999;59(2):431-5. 
14. Weinzierl AO, Maurer D, Altenberend F, Schneiderhan-Marra N, Klingel K, Schoor O, et al. A cryptic 
vascular endothelial growth factor T-cell epitope: identification and characterization by mass 
spectrometry and T-cell assays. Cancer Res. 2008;68(7):2447-54. 
15. Kang X, Kawakami Y, el-Gamil M, Wang R, Sakaguchi K, Yannelli JR, et al. Identification of a 
tyrosinase epitope recognized by HLA-A24-restricted, tumor-infiltrating lymphocytes. J Immunol. 
1995;155(3):1343-8. 
16. Gold P, Freedman SO. Demonstration of Tumor-Specific Antigens in Human Colonic Carcinomata by 
Immunological Tolerance and Absorption Techniques. J Exp Med. 1965;121:439-62. 
17. Coulie PG, Brichard V, Van Pel A, Wolfel T, Schneider J, Traversari C, et al. A new gene coding for a 
differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J 
Exp Med. 1994;180(1):35-42. 
18. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, et al. Safety and persistence of 
adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy 
refractory B-cell leukemias. Blood. 2011;118(18):4817-28. 
19. Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell 
therapy for acute lymphoblastic leukemia. Blood. 2015;125(26):4017-23. 
20. Parkhurst MR, Yang JC, Langan RC, Dudley ME, Nathan DA, Feldman SA, et al. T cells targeting 
carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce 
severe transient colitis. Mol Ther. 2011;19(3):620-6. 
21. Akers SN, Odunsi K, Karpf AR. Regulation of cancer germline antigen gene expression: implications 
for cancer immunotherapy. Future Oncol. 2010;6(5):717-32. 
22. Sang M, Lian Y, Zhou X, Shan B. MAGE-A family: attractive targets for cancer immunotherapy. 
Vaccine. 2011;29(47):8496-500. 
23. Coulie PG, Van den Eynde BJ, van der Bruggen P, Boon T. Tumour antigens recognized by T 
lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135-46. 
 
53 
 
24. Vigneron N. Human Tumor Antigens and Cancer Immunotherapy. BioMed research international. 
2015;2015:948501. 
25. Schietinger A, Philip M, Schreiber H. Specificity in cancer immunotherapy. Seminars in immunology. 
2008;20(5):276-85. 
26. Gjertsen MK, Bjorheim J, Saeterdal I, Myklebust J, Gaudernack G. Cytotoxic CD4+ and CD8+ T 
lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 
12Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour 
cells carrying this mutation. Int J Cancer. 1997;72(5):784-90. 
27. Leisegang M, Engels B, Schreiber K, Yew PY, Kiyotani K, Idel C, et al. Eradication of Large Solid 
Tumors by Gene Therapy with a T-Cell Receptor Targeting a Single Cancer-Specific Point Mutation. 
Clin Cancer Res. 2016;22(11):2734-43. 
28. Roberts SA, Gordenin DA. Hypermutation in human cancer genomes: footprints and mechanisms. 
Nat Rev Cancer. 2014;14(12):786-800. 
29. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, et al. Signatures of 
mutational processes in human cancer. Nature. 2013;500(7463):415-21. 
30. Tran E, Turcotte S, Gros A, Robbins PF, Lu YC, Dudley ME, et al. Cancer immunotherapy based on 
mutation-specific CD4+ T cells in a patient with epithelial cancer. Science. 2014;344(6184):641-5. 
31. Swann JB, Smyth MJ. Immune surveillance of tumors. J Clin Invest. 2007;117(5):1137-46. 
32. Tran E, Ahmadzadeh M, Lu YC, Gros A, Turcotte S, Robbins PF, et al. Immunogenicity of somatic 
mutations in human gastrointestinal cancers. Science. 2015;350(6266):1387-90. 
33. Kim R, Emi M, Tanabe K. Cancer immunoediting from immune surveillance to immune escape. 
Immunology. 2007;121(1):1-14. 
34. Ehrlich P. Über den jetzigen Stand der Karzinomforschung. Beiträge zur experimentellen Pathologie 
und Chemotherapie. 1909:117-64. 
35. Ehrlich P. The Collected Papers of Paul Ehrlich. Journal of the Royal Society of Medicine. 1957;50. 
36. Burnet M. Cancer: a biological approach. III. Viruses associated with neoplastic conditions. IV. 
Practical applications. Br Med J. 1957;1(5023):841-7. 
37. Clark WH, Jr., Elder DE, Guerry Dt, Braitman LE, Trock BJ, Schultz D, et al. Model predicting survival 
in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81(24):1893-904. 
38. Zhang L, Conejo-Garcia JR, Katsaros D, Gimotty PA, Massobrio M, Regnani G, et al. Intratumoral T 
cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348(3):203-13. 
39. Ishigami S, Natsugoe S, Tokuda K, Nakajo A, Che X, Iwashige H, et al. Prognostic value of 
intratumoral natural killer cells in gastric carcinoma. Cancer. 2000;88(3):577-83. 
40. Villegas FR, Coca S, Villarrubia VG, Jimenez R, Chillon MJ, Jareno J, et al. Prognostic significance of 
tumor infiltrating natural killer cells subset CD57 in patients with squamous cell lung cancer. Lung 
Cancer. 2002;35(1):23-8. 
41. Coca S, Perez-Piqueras J, Martinez D, Colmenarejo A, Saez MA, Vallejo C, et al. The prognostic 
significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer. 
1997;79(12):2320-8. 
42. Smyth MJ, Thia KY, Street SE, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity 
is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192(5):755-60. 
43. Restifo NP, Dudley ME, Rosenberg SA. Adoptive immunotherapy for cancer: harnessing the T cell 
response. Nat Rev Immunol. 2012;12(4):269-81. 
44. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of 
tumor cells expressing dominant negative IFN gamma receptors. Immunity. 1994;1(6):447-56. 
45. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, et al. Demonstration of an 
interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl 
Acad Sci U S A. 1998;95(13):7556-61. 
46. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control 
tumor initiation, growth, and metastasis. Blood. 2001;97(1):192-7. 
47. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 
2004;22:329-60. 
 
54 
 
48. von Bernstorff W, Voss M, Freichel S, Schmid A, Vogel I, Johnk C, et al. Systemic and local 
immunosuppression in pancreatic cancer patients. Clin Cancer Res. 2001;7(3 Suppl):925s-32s. 
49. Stronen E, Toebes M, Kelderman S, van Buuren MM, Yang W, van Rooij N, et al. Targeting of cancer 
neoantigens with donor-derived T cell receptor repertoires. Science. 2016;352(6291):1337-41. 
50. Radoja S, Rao TD, Hillman D, Frey AB. Mice bearing late-stage tumors have normal functional 
systemic T cell responses in vitro and in vivo. J Immunol. 2000;164(5):2619-28. 
51. Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on 
cancer cells. Blood. 2008;111(7):3635-43. 
52. Juneja VR, McGuire KA, Manguso RT, LaFleur MW, Collins N, Haining WN, et al. PD-L1 on tumor 
cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. J 
Exp Med. 2017;214(4):895-904. 
53. Lau J, Cheung J, Navarro A, Lianoglou S, Haley B, Totpal K, et al. Tumour and host cell PD-L1 is 
required to mediate suppression of anti-tumour immunity in mice. Nat Commun. 2017;8:14572. 
54. Kataoka T, Schroter M, Hahne M, Schneider P, Irmler M, Thome M, et al. FLIP prevents apoptosis 
induced by death receptors but not by perforin/granzyme B, chemotherapeutic drugs, and gamma 
irradiation. J Immunol. 1998;161(8):3936-42. 
55. Huber V, Fais S, Iero M, Lugini L, Canese P, Squarcina P, et al. Human colorectal cancer cells induce 
T-cell death through release of proapoptotic microvesicles: role in immune escape. 
Gastroenterology. 2005;128(7):1796-804. 
56. Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S, et al. Vascular endothelial growth 
factor inhibits the development of dendritic cells and dramatically affects the differentiation of 
multiple hematopoietic lineages in vivo. Blood. 1998;92(11):4150-66. 
57. Kim R, Emi M, Tanabe K. Cancer cell immune escape and tumor progression by exploitation of anti-
inflammatory and pro-inflammatory responses. Cancer Biol Ther. 2005;4(9):924-33. 
58. Campoli M, Chang CC, Ferrone S. HLA class I antigen loss, tumor immune escape and immune 
selection. Vaccine. 2002;20 Suppl 4:A40-5. 
59. Raghavan S, Quiding-Jarbrink M. Regulatory T cells in gastrointestinal tumors. Expert Rev 
Gastroenterol Hepatol. 2011;5(4):489-501. 
60. Ventola CL. Cancer Immunotherapy, Part 1: Current Strategies and Agents. P T. 2017;42(6):375-83. 
61. Tan SY, Grimes S. Paul Ehrlich (1854-1915): man with the magic bullet. Singapore Med J. 
2010;51(11):842-3. 
62. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 
2012;12(4):252-64. 
63. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator 
approach to cancer therapy. Cancer Cell. 2015;27(4):450-61. 
64. Davis KL, Agarwal AM, Verma AR. Checkpoint inhibition in pediatric hematologic malignancies. 
Pediatr Hematol Oncol. 2017;34(6-7):379-94. 
65. Topp MS, Kufer P, Gokbuget N, Goebeler M, Klinger M, Neumann S, et al. Targeted therapy with 
the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease 
in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged 
leukemia-free survival. J Clin Oncol. 2011;29(18):2493-8. 
66. Alatrash G, Jakher H, Stafford PD, Mittendorf EA. Cancer immunotherapies, their safety and 
toxicity. Expert Opin Drug Saf. 2013;12(5):631-45. 
67. Slingluff CL, Jr. The present and future of peptide vaccines for cancer: single or multiple, long or 
short, alone or in combination? Cancer J. 2011;17(5):343-50. 
68. Toes RE, Offringa R, Blom RJ, Melief CJ, Kast WM. Peptide vaccination can lead to enhanced tumor 
growth through specific T-cell tolerance induction. Proc Natl Acad Sci U S A. 1996;93(15):7855-60. 
69. Slingluff CL, Jr., Petroni GR, Olson W, Czarkowski A, Grosh WW, Smolkin M, et al. Helper T-cell 
responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and 
melanocytic differentiation antigens. J Clin Oncol. 2008;26(30):4973-80. 
70. Schwartzentruber DJ, Lawson DH, Richards JM, Conry RM, Miller DM, Treisman J, et al. gp100 
peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 
2011;364(22):2119-27. 
 
55 
 
71. Mittendorf EA, Clifton GT, Holmes JP, Clive KS, Patil R, Benavides LC, et al. Clinical trial results of the 
HER-2/neu (E75) vaccine to prevent breast cancer recurrence in high-risk patients: from US Military 
Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2012;118(10):2594-602. 
72. Kotsakis A, Papadimitraki E, Vetsika EK, Aggouraki D, Dermitzaki EK, Hatzidaki D, et al. A phase II 
trial evaluating the clinical and immunologic response of HLA-A2(+) non-small cell lung cancer 
patients vaccinated with an hTERT cryptic peptide. Lung Cancer. 2014;86(1):59-66. 
73. Suzuki N, Hazama S, Iguchi H, Uesugi K, Tanaka H, Hirakawa K, et al. Phase II clinical trial of peptide 
cocktail therapy for patients with advanced pancreatic cancer: VENUS-PC study. Cancer Sci. 
2017;108(1):73-80. 
74. Iinuma H, Fukushima R, Inaba T, Tamura J, Inoue T, Ogawa E, et al. Phase I clinical study of multiple 
epitope peptide vaccine combined with chemoradiation therapy in esophageal cancer patients. J 
Transl Med. 2014;12:84. 
75. Fujiwara Y, Okada K, Omori T, Sugimura K, Miyata H, Ohue M, et al. Multiple therapeutic peptide 
vaccines for patients with advanced gastric cancer. Int J Oncol. 2017;50(5):1655-62. 
76. Schuler PJ, Harasymczuk M, Visus C, Deleo A, Trivedi S, Lei Y, et al. Phase I dendritic cell p53 
peptide vaccine for head and neck cancer. Clin Cancer Res. 2014;20(9):2433-44. 
77. Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, et al. Use of tumor-
infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic 
melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676-80. 
78. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer 
regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. 
Science. 2002;298(5594):850-4. 
79. Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. 
Science. 2015;348(6230):62-8. 
80. Merhavi-Shoham E, Itzhaki O, Markel G, Schachter J, Besser MJ. Adoptive Cell Therapy for 
Metastatic Melanoma. Cancer J. 2017;23(1):48-53. 
81. Jochems C, Schlom J. Tumor-infiltrating immune cells and prognosis: the potential link between 
conventional cancer therapy and immunity. Exp Biol Med (Maywood). 2011;236(5):567-79. 
82. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, et al. Phenotypic and 
functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the 
tumour phenotype. Cancer Immunol Immunother. 1992;34(4):241-51. 
83. Barrett DM, Grupp SA, June CH. Chimeric Antigen Receptor- and TCR-Modified T Cells Enter Main 
Street and Wall Street. J Immunol. 2015;195(3):755-61. 
84. Sadelain M, Brentjens R, Riviere I. The basic principles of chimeric antigen receptor design. Cancer 
discovery. 2013;3(4):388-98. 
85. Yang S, Rosenberg SA, Morgan RA. Clinical-scale lentiviral vector transduction of PBL for TCR gene 
therapy and potential for expression in less-differentiated cells. J Immunother. 2008;31(9):830-9. 
86. Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, et al. Cancer regression in 
patients after transfer of genetically engineered lymphocytes. Science. 2006;314(5796):126-9. 
87. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. 
Curr Opin Immunol. 2009;21(2):215-23. 
88. Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric 
antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267-76. 
89. Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, et al. 
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be 
effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin 
Oncol. 2015;33(6):540-9. 
90. Firor AE, Jares A, Ma Y. From humble beginnings to success in the clinic: Chimeric antigen receptor-
modified T-cells and implications for immunotherapy. Exp Biol Med (Maywood). 2015;240(8):1087-
98. 
91. Johnson LA, Morgan RA, Dudley ME, Cassard L, Yang JC, Hughes MS, et al. Gene therapy with 
human and mouse T-cell receptors mediates cancer regression and targets normal tissues 
expressing cognate antigen. Blood. 2009;114(3):535-46. 
 
56 
 
92. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-
derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T 
cells. Sci Transl Med. 2013;5(197):197ra03. 
93. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular 
toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood. 
2013;122(6):863-71. 
94. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression 
and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 
2013;36(2):133-51. 
95. Arora RS, Alston RD, Eden TO, Estlin EJ, Moran A, Birch JM. Age-incidence patterns of primary CNS 
tumors in children, adolescents, and adults in England. Neuro Oncol. 2009;11(4):403-13. 
96. Buckner JC, Brown PD, O'Neill BP, Meyer FB, Wetmore CJ, Uhm JH. Central nervous system tumors. 
Mayo Clin Proc. 2007;82(10):1271-86. 
97. Fogarty MP, Kessler JD, Wechsler-Reya RJ. Morphing into cancer: the role of developmental 
signaling pathways in brain tumor formation. J Neurobiol. 2005;64(4):458-75. 
98. Alston RD, Newton R, Kelsey A, Newbould MJ, Birch JM, Lawson B, et al. Childhood 
medulloblastoma in northwest England 1954 to 1997: incidence and survival. Dev Med Child 
Neurol. 2003;45(5):308-14. 
99. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, et al. The 
2016 World Health Organization Classification of Tumors of the Central Nervous System: a 
summary. Acta Neuropathol. 2016;131(6):803-20. 
100. Roussel MF, Hatten ME. Cerebellum development and medulloblastoma. Curr Top Dev Biol. 
2011;94:235-82. 
101. Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, et al. Medulloblastoma Genotype 
Dictates Blood Brain Barrier Phenotype. Cancer Cell. 2016;29(4):508-22. 
102. Ellison DW, Dalton J, Kocak M, Nicholson SL, Fraga C, Neale G, et al. Medulloblastoma: 
clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups. Acta 
Neuropathol. 2011;121(3):381-96. 
103. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, et al. The 2007 WHO 
classification of tumours of the central nervous system. Acta Neuropathol. 2007;114(2):97-109. 
104. Jones DT, Jager N, Kool M, Zichner T, Hutter B, Sultan M, et al. Dissecting the genomic complexity 
underlying medulloblastoma. Nature. 2012;488(7409):100-5. 
105. Robinson G, Parker M, Kranenburg TA, Lu C, Chen X, Ding L, et al. Novel mutations target distinct 
subgroups of medulloblastoma. Nature. 2012;488(7409):43-8. 
106. Pugh TJ, Weeraratne SD, Archer TC, Pomeranz Krummel DA, Auclair D, Bochicchio J, et al. 
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature. 
2012;488(7409):106-10. 
107. Archer TC, Pomeroy SL. Medulloblastoma biology in the post-genomic era. Future Oncol. 
2012;8(12):1597-604. 
108. Northcott PA, Buchhalter I, Morrissy AS, Hovestadt V, Weischenfeldt J, Ehrenberger T, et al. The 
whole-genome landscape of medulloblastoma subtypes. Nature. 2017;547(7663):311-7. 
109. Rutkowski S, von Hoff K, Emser A, Zwiener I, Pietsch T, Figarella-Branger D, et al. Survival and 
prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol. 
2010;28(33):4961-8. 
110. Gajjar A, Chintagumpala M, Ashley D, Kellie S, Kun LE, Merchant TE, et al. Risk-adapted craniospinal 
radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly 
diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, 
multicentre trial. Lancet Oncol. 2006;7(10):813-20. 
111. Mabbott DJ, Penkman L, Witol A, Strother D, Bouffet E. Core neurocognitive functions in children 
treated for posterior fossa tumors. Neuropsychology. 2008;22(2):159-68. 
112. Sabel M, Fleischhack G, Tippelt S, Gustafsson G, Doz F, Kortmann R, et al. Relapse patterns and 
outcome after relapse in standard risk medulloblastoma: a report from the HIT-SIOP-PNET4 study. J 
Neurooncol. 2016;129(3):515-24. 
 
57 
 
113. Hill RM, Kuijper S, Lindsey JC, Petrie K, Schwalbe EC, Barker K, et al. Combined MYC and P53 defects 
emerge at medulloblastoma relapse and define rapidly progressive, therapeutically targetable 
disease. Cancer Cell. 2015;27(1):72-84. 
114. Koschmann C, Bloom K, Upadhyaya S, Geyer JR, Leary SE. Survival After Relapse of 
Medulloblastoma. J Pediatr Hematol Oncol. 2016;38(4):269-73. 
115. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC 
ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-9. 
116. Blaeschke F, Paul MC, Schuhmann MU, Rabsteyn A, Schroeder C, Casadei N, et al. Low mutational 
load in pediatric medulloblastoma still translates into neoantigens as targets for specific T-cell 
immunotherapy. Cytotherapy. 2019;21(9):973-86. 
117. Dhall G. Medulloblastoma. J Child Neurol. 2009;24(11):1418-30. 
118. Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med. 
1996;183(3):725-9. 
119. Cohen CJ, Gartner JJ, Horovitz-Fried M, Shamalov K, Trebska-McGowan K, Bliskovsky VV, et al. 
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes. J Clin Invest. 
2015;125(10):3981-91. 
120. Popovic J, Li LP, Kloetzel PM, Leisegang M, Uckert W, Blankenstein T. The only proposed T-cell 
epitope derived from the TEL-AML1 translocation is not naturally processed. Blood. 
2011;118(4):946-54. 
121. Parker KC, Shields M, DiBrino M, Brooks A, Coligan JE. Peptide binding to MHC class I molecules: 
implications for antigenic peptide prediction. Immunol Res. 1995;14(1):34-57. 
122. Matsushita H, Vesely MD, Koboldt DC, Rickert CG, Uppaluri R, Magrini VJ, et al. Cancer exome 
analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature. 
2012;482(7385):400-4. 
123. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, et al. Mining exomic sequencing data to 
identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat Med. 
2013;19(6):747-52. 
124. Schreiber H, Rowley JD, Rowley DA. Targeting mutations predictably. Blood. 2011;118(4):830-1. 
125. Paul S, Weiskopf D, Angelo MA, Sidney J, Peters B, Sette A. HLA class I alleles are associated with 
peptide-binding repertoires of different size, affinity, and immunogenicity. J Immunol. 
2013;191(12):5831-9. 
126. Engels B, Engelhard VH, Sidney J, Sette A, Binder DC, Liu RB, et al. Relapse or eradication of cancer 
is predicted by peptide-major histocompatibility complex affinity. Cancer Cell. 2013;23(4):516-26. 
127. Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules 
integrating information from multiple receptor and peptide length datasets. Genome Med. 
2016;8(1):33. 
128. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II 
epitopes drive therapeutic immune responses to cancer. Nature. 2015;520(7549):692-6. 
129. Schellens IM, Hoof I, Meiring HD, Spijkers SN, Poelen MC, van Gaans-van den Brink JA, et al. 
Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A 
and B in the Immunopeptidome. PLoS One. 2015;10(9):e0136417. 
130. Fruci D, Rovero P, Falasca G, Chersi A, Sorrentino R, Butler R, et al. Anchor residue motifs of HLA 
class-I-binding peptides analyzed by the direct binding of synthetic peptides to HLA class I alpha 
chains. Hum Immunol. 1993;38(3):187-92. 
131. Khalili JS, Hanson RW, Szallasi Z. In silico prediction of tumor antigens derived from functional 
missense mutations of the cancer gene census. Oncoimmunology. 2012;1(8):1281-9. 
132. Kambayashi T, Laufer TM. Atypical MHC class II-expressing antigen-presenting cells: can anything 
replace a dendritic cell? Nat Rev Immunol. 2014;14(11):719-30. 
133. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, et al. Immature dendritic cells 
phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T 
lymphocytes. J Exp Med. 1998;188(7):1359-68. 
134. Wakim LM, Waithman J, van Rooijen N, Heath WR, Carbone FR. Dendritic cell-induced memory T 
cell activation in nonlymphoid tissues. Science. 2008;319(5860):198-202. 
 
58 
 
135. Tang-Huau TL, Gueguen P, Goudot C, Durand M, Bohec M, Baulande S, et al. Human in vivo-
generated monocyte-derived dendritic cells and macrophages cross-present antigens through a 
vacuolar pathway. Nat Commun. 2018;9(1):2570. 
136. Kuhn S, Yang J, Ronchese F. Monocyte-Derived Dendritic Cells Are Essential for CD8(+) T Cell 
Activation and Antitumor Responses After Local Immunotherapy. Front Immunol. 2015;6:584. 
137. Gabrilovich DI, Chen HL, Girgis KR, Cunningham HT, Meny GM, Nadaf S, et al. Production of 
vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic 
cells. Nat Med. 1996;2(10):1096-103. 
138. Menetrier-Caux C, Montmain G, Dieu MC, Bain C, Favrot MC, Caux C, et al. Inhibition of the 
differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and 
macrophage colony-stimulating factor. Blood. 1998;92(12):4778-91. 
139. Ahrends T, Spanjaard A, Pilzecker B, Babala N, Bovens A, Xiao Y, et al. CD4(+) T Cell Help Confers a 
Cytotoxic T Cell Effector Program Including Coinhibitory Receptor Downregulation and Increased 
Tissue Invasiveness. Immunity. 2017;47(5):848-61 e5. 
140. Bevan MJ. Helping the CD8(+) T-cell response. Nat Rev Immunol. 2004;4(8):595-602. 
141. Castellino F, Germain RN. Cooperation between CD4+ and CD8+ T cells: when, where, and how. 
Annu Rev Immunol. 2006;24:519-40. 
142. Dudley ME, Wunderlich JR, Shelton TE, Even J, Rosenberg SA. Generation of tumor-infiltrating 
lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother. 
2003;26(4):332-42. 
143. Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: 
impact on clinical outcome. Nat Rev Cancer. 2012;12(4):298-306. 
144. Schoenberger SP, Toes RE, van der Voort EI, Offringa R, Melief CJ. T-cell help for cytotoxic T 
lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480-3. 
145. Voest EE, Kenyon BM, O'Reilly MS, Truitt G, D'Amato RJ, Folkman J. Inhibition of angiogenesis in 
vivo by interleukin 12. J Natl Cancer Inst. 1995;87(8):581-6. 
146. Sun JC, Bevan MJ. Defective CD8 T cell memory following acute infection without CD4 T cell help. 
Science. 2003;300(5617):339-42. 
147. Shedlock DJ, Whitmire JK, Tan J, MacDonald AS, Ahmed R, Shen H. Role of CD4 T cell help and 
costimulation in CD8 T cell responses during Listeria monocytogenes infection. J Immunol. 
2003;170(4):2053-63. 
148. Muccioli M, Longstaff C, Benencia F. Absence of CD4 T-cell help provides a robust CD8 T-cell 
response while inducing effective memory in a preclinical model of melanoma. Immunotherapy. 
2012;4(5):477-81. 
149. Jensen KK, Andreatta M, Marcatili P, Buus S, Greenbaum JA, Yan Z, et al. Improved methods for 
predicting peptide binding affinity to MHC class II molecules. Immunology. 2018;154(3):394-406. 
150. Nielsen M, Lund O, Buus S, Lundegaard C. MHC class II epitope predictive algorithms. Immunology. 
2010;130(3):319-28. 
151. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, et al. Pillars article: three-
dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature. 1993. 364: 
33-39. J Immunol. 2015;194(1):5-11. 
152. Chalmers ZR, Connelly CF, Fabrizio D, Gay L, Ali SM, Ennis R, et al. Analysis of 100,000 human 
cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9(1):34. 
153. Chen L, Tanriover G, Yano H, Friedlander R, Louvi A, Gunel M. Apoptotic functions of 
PDCD10/CCM3, the gene mutated in cerebral cavernous malformation 3. Stroke. 2009;40(4):1474-
81. 
154. Lauenborg B, Kopp K, Krejsgaard T, Eriksen KW, Geisler C, Dabelsteen S, et al. Programmed cell 
death-10 enhances proliferation and protects malignant T cells from apoptosis. APMIS. 
2010;118(10):719-28. 
155. He Y, Zhang H, Yu L, Gunel M, Boggon TJ, Chen H, et al. Stabilization of VEGFR2 signaling by 
cerebral cavernous malformation 3 is critical for vascular development. Sci Signal. 
2010;3(116):ra26. 
 
59 
 
156. Cigoli MS, Avemaria F, De Benedetti S, Gesu GP, Accorsi LG, Parmigiani S, et al. PDCD10 gene 
mutations in multiple cerebral cavernous malformations. PLoS One. 2014;9(10):e110438. 
157. Cameron J, Holla OL, Ranheim T, Kulseth MA, Berge KE, Leren TP. Effect of mutations in the PCSK9 
gene on the cell surface LDL receptors. Hum Mol Genet. 2006;15(9):1551-8. 
158. Xu X, Cui Y, Cao L, Zhang Y, Yin Y, Hu X. PCSK9 regulates apoptosis in human lung adenocarcinoma 
A549 cells via endoplasmic reticulum stress and mitochondrial signaling pathways. Exp Ther Med. 
2017;13(5):1993-9. 
159. Mukohara T. PI3K mutations in breast cancer: prognostic and therapeutic implications. Breast 
Cancer (Dove Med Press). 2015;7:111-23. 
160. Scheffler M, Bos M, Gardizi M, Konig K, Michels S, Fassunke J, et al. PIK3CA mutations in non-small 
cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior 
malignancies. Oncotarget. 2015;6(2):1315-26. 
161. Cathomas G. PIK3CA in Colorectal Cancer. Front Oncol. 2014;4:35. 
162. Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE, et al. Mutations of PIK3CA 
in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res. 
2004;64(15):5048-50. 
163. Guerreiro AS, Fattet S, Fischer B, Shalaby T, Jackson SP, Schoenwaelder SM, et al. Targeting the 
PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration. 
Clin Cancer Res. 2008;14(21):6761-9. 
164. Hevner RF. Brain overgrowth in disorders of RTK-PI3K-AKT signaling: a mosaic of malformations. 
Semin Perinatol. 2015;39(1):36-43. 
165. Adams HH, Hibar DP, Chouraki V, Stein JL, Nyquist PA, Renteria ME, et al. Novel genetic loci 
underlying human intracranial volume identified through genome-wide association. Nat Neurosci. 
2016;19(12):1569-82. 
166. Miller TW, Rexer BN, Garrett JT, Arteaga CL. Mutations in the phosphatidylinositol 3-kinase 
pathway: role in tumor progression and therapeutic implications in breast cancer. Breast Cancer 
Res. 2011;13(6):224. 
167. Carraway KL, Theodoropoulos G, Kozloski GA, Carothers Carraway CA. Muc4/MUC4 functions and 
regulation in cancer. Future Oncol. 2009;5(10):1631-40. 
168. Chaturvedi P, Singh AP, Moniaux N, Senapati S, Chakraborty S, Meza JL, et al. MUC4 mucin 
potentiates pancreatic tumor cell proliferation, survival, and invasive properties and interferes with 
its interaction to extracellular matrix proteins. Mol Cancer Res. 2007;5(4):309-20. 
169. Ponnusamy MP, Singh AP, Jain M, Chakraborty S, Moniaux N, Batra SK. MUC4 activates HER2 
signalling and enhances the motility of human ovarian cancer cells. Br J Cancer. 2008;99(3):520-6. 
170. Mukhopadhyay P, Lakshmanan I, Ponnusamy MP, Chakraborty S, Jain M, Pai P, et al. MUC4 
overexpression augments cell migration and metastasis through EGFR family proteins in triple 
negative breast cancer cells. PLoS One. 2013;8(2):e54455. 
171. Nicholson CL, Plautz GE. Cure of Murine Medulloblastoma by Adoptive Transfer of Tumor-Specific T 
Cells. 2007;110(11):4904-. 
172. Clemente CG, Mihm MC, Jr., Bufalino R, Zurrida S, Collini P, Cascinelli N. Prognostic value of tumor 
infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer. 
1996;77(7):1303-10. 
173. Vermeulen JF, Van Hecke W, Adriaansen EJM, Jansen MK, Bouma RG, Villacorta Hidalgo J, et al. 
Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric 
medulloblastoma. Oncoimmunology. 2018;7(3):e1398877. 
174. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ, et al. Durable complete 
responses in heavily pretreated patients with metastatic melanoma using T-cell transfer 
immunotherapy. Clin Cancer Res. 2011;17(13):4550-7. 
175. Rohaan MW, Wilgenhof S, Haanen J. Adoptive cellular therapies: the current landscape. Virchows 
Arch. 2018. 
176. Goodman AM, Kato S, Bazhenova L, Patel SP, Frampton GM, Miller V, et al. Tumor Mutational 
Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers. Mol 
Cancer Ther. 2017;16(11):2598-608. 
 
60 
 
177. McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens 
elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 
2016;351(6280):1463-9. 
178. Sayour EJ, Mitchell DA. Immunotherapy for Pediatric Brain Tumors. Brain Sci. 2017;7(10). 
179. Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, et al. Pilot study of mutant 
ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer 
Immunol Immunother. 2008;57(9):1413-20. 
180. Schuster J, Lai RK, Recht LD, Reardon DA, Paleologos NA, Groves MD, et al. A phase II, multicenter 
trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 
2015;17(6):854-61. 
181. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, et al. 
Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature. 
2016;536(7614):91-5. 
182. Chu Y, Liu Q, Wei J, Liu B. Personalized cancer neoantigen vaccines come of age. Theranostics. 
2018;8(15):4238-46. 
183. Carreno BM, Magrini V, Becker-Hapak M, Kaabinejadian S, Hundal J, Petti AA, et al. Cancer 
immunotherapy. A dendritic cell vaccine increases the breadth and diversity of melanoma 
neoantigen-specific T cells. Science. 2015;348(6236):803-8. 
184. Bijker MS, Melief CJ, Offringa R, van der Burg SH. Design and development of synthetic peptide 
vaccines: past, present and future. Expert Rev Vaccines. 2007;6(4):591-603. 
185. Quakkelaar ED, Melief CJ. Experience with synthetic vaccines for cancer and persistent virus 
infections in nonhuman primates and patients. Adv Immunol. 2012;114:77-106. 
186. Vidard L, Colarusso LJ, Benacerraf B. Specific T-cell tolerance may be preceded by a primary 
response. Proc Natl Acad Sci U S A. 1994;91(12):5627-31. 
187. Jenkins MK. The ups and downs of T cell costimulation. Immunity. 1994;1(6):443-6. 
188. Aichele P, Brduscha-Riem K, Zinkernagel RM, Hengartner H, Pircher H. T cell priming versus T cell 
tolerance induced by synthetic peptides. J Exp Med. 1995;182(1):261-6. 
189. Kumai T, Fan A, Harabuchi Y, Celis E. Cancer immunotherapy: moving forward with peptide T cell 
vaccines. Curr Opin Immunol. 2017;47:57-63. 
190. Cho HI, Barrios K, Lee YR, Linowski AK, Celis E. BiVax: a peptide/poly-IC subunit vaccine that mimics 
an acute infection elicits vast and effective anti-tumor CD8 T-cell responses. Cancer Immunol 
Immunother. 2013;62(4):787-99. 
191. Gattinoni L, Klebanoff CA, Palmer DC, Wrzesinski C, Kerstann K, Yu Z, et al. Acquisition of full 
effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively 
transferred CD8+ T cells. J Clin Invest. 2005;115(6):1616-26. 
192. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, et al. Chimeric 
antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior 
antitumor reactivity in vivo. Leukemia. 2016;30(2):492-500. 
193. Steeber DA, Green NE, Sato S, Tedder TF. Lyphocyte migration in L-selectin-deficient mice. Altered 
subset migration and aging of the immune system. J Immunol. 1996;157(3):1096-106. 
194. Lee D, Schultz JB, Knauf PA, King MR. Mechanical shedding of L-selectin from the neutrophil surface 
during rolling on sialyl Lewis x under flow. J Biol Chem. 2007;282(7):4812-20. 
195. Kishimoto TK, Jutila MA, Berg EL, Butcher EC. Neutrophil Mac-1 and MEL-14 adhesion proteins 
inversely regulated by chemotactic factors. Science. 1989;245(4923):1238-41. 
196. Fan H, Derynck R. Ectodomain shedding of TGF-alpha and other transmembrane proteins is 
induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J. 
1999;18(24):6962-72. 
197. E. John Wherry MK. Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol. 
2015;15:486–99. 
 
61 
 
G Appendix 
1 Supplementary data 
 
Table 9: Overview of donor/peptide combinations tested for de novo T-cell responses. 
All tested peptides are included, whether they induced a positive T-cell response (+) or not (-). Peptide 15 was tested twice with 
the same donor, positive in the first and negative in the second run. Peptide 9 and peptide 21 were tested with HLA B*18:01 (a) 
as well as with B*44:02 (b). Since donor 10 had both HLA types, it is unclear which one mediated the positive response against 
each peptide (c). P = peptide 
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